var title_f7_13_7376="Dermal sinus";
var content_f7_13_7376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermal sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dermal sinus lesions may predispose to meningitis with",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    , Coagulase-negative staphylococci, and enteric Gram-negative organisms, such as",
"    <em>",
"     Escherichia coli",
"    </em>",
"    and",
"    <em>",
"     Klebsiella",
"    </em>",
"    species.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sheldon L Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7376=[""].join("\n");
var outline_f7_13_7376=null;
var title_f7_13_7377="Clobenzorex: International drug information";
var content_f7_13_7377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clobenzorex: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Asenlix (MX);",
"     </li>",
"     <li>",
"      Dinintel (ES, FR, PT);",
"     </li>",
"     <li>",
"      Finedal (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Clobenzorex Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An anorectic used in the management of obesity",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 30 mg twice daily before meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 30 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10359 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7377=[""].join("\n");
var outline_f7_13_7377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304141\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978374\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978376\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978379\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978375\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821231\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978378\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10359|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7378="Patient information: Dysphagia (The Basics)";
var content_f7_13_7378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17168\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"         Upper digestive tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?30/7/30843\">",
"          Medicines used to treat acid reflux",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/54/39778\">",
"         Patient information: Eosinophilic esophagitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/14/14562\">",
"         Patient information: Myasthenia gravis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dysphagia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dysphagia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29125278\">",
"      <span class=\"h1\">",
"       What is dysphagia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dysphagia is the medical term for &ldquo;trouble swallowing.&rdquo; Sometimes, dysphagia happens if you eat too fast or don&rsquo;t chew your food well enough. But if you have dysphagia, you might have a serious medical problem that needs to be treated right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29125293\">",
"      <span class=\"h1\">",
"       What causes dysphagia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dysphagia is usually caused by a problem in the upper part of your digestive tract (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"       figure 1",
"      </a>",
"      ). Often, the problem is in the esophagus, tube that connects your mouth to your stomach. But it can also happen because of a problem in the mouth or throat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29125308\">",
"      <span class=\"h1\">",
"       What are the symptoms of dysphagia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not being able to swallow",
"       </li>",
"       <li>",
"        Pain while swallowing",
"       </li>",
"       <li>",
"        Feeling like food is stuck in your throat or chest",
"       </li>",
"       <li>",
"        Coughing or gagging while swallowing",
"       </li>",
"       <li>",
"        Drooling",
"       </li>",
"       <li>",
"        Trouble speaking",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29125323\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have any of the above symptoms. Do so right away if you are unable to swallow your own saliva and are drooling or have trouble speaking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29125338\">",
"      <span class=\"h1\">",
"       Are there tests for dysphagia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and ask about your symptoms. Other test might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"         barium",
"        </a>",
"        X-ray &ndash; For this test, you drink a thick liquid called a &ldquo;barium solution.&rdquo; It coats the inside of your esophagus. The barium shows up on X-rays, so the doctor can see any problems in the esophagus.",
"       </li>",
"       <li>",
"        A swallowing study &ndash; For this test, you eat different foods coated with",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"         barium",
"        </a>",
"        . X-rays taken at different time points during the test show if you have problems with the muscles in your mouth or throat. This test is also called a &ldquo;videofluoroscopy.&rdquo;",
"       </li>",
"       <li>",
"        Upper endoscopy &ndash; For this test, the doctor puts a thin, flexible tube into your mouth, down your throat, and into your esophagus. The tube (called an endoscope) has a camera and a light on it, so it allows the doctor to see inside the esophagus.",
"       </li>",
"       <li>",
"        Manometry &ndash; For this test, the doctor puts a small tube that measures the pressure in your esophagus. The readings show how well the muscles that help you swallow are working.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29125353\">",
"      <span class=\"h1\">",
"       How is dysphagia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on what is causing the dysphagia.",
"     </p>",
"     <p>",
"      If you have dysphagia because of a problem in your mouth and the upper part of your throat, your doctor might refer you to a speech or swallowing specialist who can teach you exercises to help you swallow.",
"     </p>",
"     <p>",
"      If the problem affects your esophagus, treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Esophageal dilation &ndash; For this procedure, the doctor uses an endoscope (see above) with a special balloon on the end to gently stretch and widen your esophagus.",
"       </li>",
"       <li>",
"        Surgery &ndash; Doctors can do surgery to remove any tumors or other abnormal tissue in the esophagus.",
"       </li>",
"       <li>",
"        Medicines &ndash; Medicines used to treat dysphagia include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Medicines that reduce stomach acid, such as proton pump inhibitors (",
"        <a class=\"graphic graphic_table graphicRef78918 \" href=\"UTD.htm?30/7/30843\">",
"         table 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Medicines to treat an infection of the esophagus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29125368\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/54/39778?source=see_link\">",
"       Patient information: Eosinophilic esophagitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=see_link\">",
"       Patient information: Myasthenia gravis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/13/7378?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17168 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7378=[""].join("\n");
var outline_f7_13_7378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125278\">",
"      What is dysphagia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125293\">",
"      What causes dysphagia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125308\">",
"      What are the symptoms of dysphagia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125323\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125338\">",
"      Are there tests for dysphagia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125353\">",
"      How is dysphagia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29125368\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17168\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"      Upper digestive tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?30/7/30843\">",
"       Medicines used to treat acid reflux",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/54/39778?source=related_link\">",
"      Patient information: Eosinophilic esophagitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/14/14562?source=related_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7379="Patient information: Health and nutrition for women who breastfeed (The Basics)";
var content_f7_13_7379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15827\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"         Foods and drinks with calcium and vitamin D",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/43/17075\">",
"         Patient information: Breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/19/38194\">",
"         Patient information: Deciding to breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/49/30484\">",
"         Patient information: Anemia caused by low iron (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/19/1333\">",
"         Patient information: Breastfeeding guide (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/63/34805\">",
"         Patient information: Deciding to breastfeed (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/54/31588\">",
"         Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Health and nutrition for women who breastfeed (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/health-and-nutrition-for-women-who-breastfeed-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30443893\">",
"      <span class=\"h1\">",
"       Do women who breastfeed need to eat more?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women who breastfeed need to eat more than women who don&rsquo;t breastfeed. People need to eat a certain number of calories each day to keep their bodies healthy. The number of calories a person needs depends on his or her age, weight, height, and how active he or she is. When a woman breastfeeds, her body works hard to make breast milk. So she needs extra calories.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443900\">",
"      <span class=\"h1\">",
"       Do women who breastfeed need to drink more?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women who breastfeed need to make sure that they drink enough fluids. To make sure that you drink enough, always drink when you feel thirsty. If you have a dry mouth or dark-colored urine, you probably need to drink more. Some women find it helpful to keep water or another non-caffeine drink nearby when they breastfeed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443907\">",
"      <span class=\"h1\">",
"       Do women who breastfeed need to take vitamins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some women need to take a daily vitamin, depending on what they eat. Women who eat meat and fish do not usually need to take a daily vitamin. But women who do not eat meat, chicken, fish, or dairy foods should take a daily vitamin that has vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      in it.",
"     </p>",
"     <p>",
"      Some women need to take an iron supplement. Supplements are pills, capsules, liquids, or tablets that have nutrients in them. You might need to take a daily iron supplement if you have a condition called &ldquo;anemia&rdquo; after you give birth.",
"     </p>",
"     <p>",
"      Women also need to make sure that they get enough calcium and vitamin D each day. Calcium and vitamin D help keep bones strong. Different foods and drinks have calcium and vitamin D (",
"      <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"       figure 1",
"      </a>",
"      ). If you do not get enough calcium and vitamin D from your food and drink, you might need to take calcium and vitamin D supplements.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443914\">",
"      <span class=\"h1\">",
"       Should women who breastfeed avoid certain foods?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women who breastfeed should avoid certain types of fish. That&rsquo;s because some types of fish have a lot of mercury in them. Mercury is a substance that can pass through the breast milk to the baby. It can cause problems with a baby&rsquo;s brain and nervous system. Fish that have a lot of mercury include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shark",
"       </li>",
"       <li>",
"        Swordfish",
"       </li>",
"       <li>",
"        King mackerel",
"       </li>",
"       <li>",
"        Tilefish",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other types of fish do not have as much mercury. Women can eat these types of fish, but not more than 2 times a week. Fish and other seafood that do not have as much mercury include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shrimp",
"       </li>",
"       <li>",
"        Canned light tuna",
"       </li>",
"       <li>",
"        Salmon",
"       </li>",
"       <li>",
"        Pollock",
"       </li>",
"       <li>",
"        Catfish",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443921\">",
"      <span class=\"h1\">",
"       Should women who breastfeed avoid certain medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. Let your doctor or nurse know if you take any medicines. He or she can make sure that those medicines are safe to take when breastfeeding.",
"     </p>",
"     <p>",
"      Some medicines can affect the amount of breast milk a woman makes. For example, some hormone birth control pills can reduce the amount of breast milk a woman makes.",
"     </p>",
"     <p>",
"      Also, doctors recommend that women who breastfeed not use illegal drugs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443928\">",
"      <span class=\"h1\">",
"       Should women who breastfeed drink alcohol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That&rsquo;s up to each woman to decide. But it&rsquo;s important to know that when you drink alcohol, some of the alcohol passes through your breast milk to your baby. After you have 1 drink, it takes about 2 hours for your body to get rid of the alcohol. Because of this, most doctors recommend that women wait 2 hours after having a drink before they breastfeed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443935\">",
"      <span class=\"h1\">",
"       Should women who breastfeed drink caffeine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. Most doctors agree that it&rsquo;s OK for women to drink 2 to 3 cups of a caffeine drink a day. But some caffeine can pass through the breast milk to the baby. Some babies can get fussy or have trouble sleeping from the caffeine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443942\">",
"      <span class=\"h1\">",
"       Should women who breastfeed smoke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Most doctors recommend that women stop or cut down on their smoking. That&rsquo;s because babies whose parents smoke can have breathing problems, lung infections, or ear infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30443949\">",
"      <span class=\"h2\">",
"       What if I have questions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have any questions about nutrition and breastfeeding, ask your doctor or nurse. Some women also find it helpful to work with a breastfeeding expert, called a &ldquo;lactation consultant.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30444083\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"       Patient information: Breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"       Patient information: Deciding to breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"       Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"       Patient information: Breastfeeding guide (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       Patient information: Deciding to breastfeed (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       Patient information: Anemia caused by low iron (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/13/7379?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15827 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-110.137.129.113-14BEEF5253-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7379=[""].join("\n");
var outline_f7_13_7379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443893\">",
"      Do women who breastfeed need to eat more?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443900\">",
"      Do women who breastfeed need to drink more?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443907\">",
"      Do women who breastfeed need to take vitamins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443914\">",
"      Should women who breastfeed avoid certain foods?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443921\">",
"      Should women who breastfeed avoid certain medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443928\">",
"      Should women who breastfeed drink alcohol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443935\">",
"      Should women who breastfeed drink caffeine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30443942\">",
"      Should women who breastfeed smoke?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30443949\">",
"      What if I have questions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30444083\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15827\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"      Foods and drinks with calcium and vitamin D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7380="Dysgerminoma";
var content_f7_13_7380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dysgerminoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of an ovarian dysgerminoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permssion from Berek JS, Hacker NF. Practical Gynecologic Oncology, 3rd ed. Lippincott Williams &amp;Wilkins, Philadelphia, 2000, p. 225.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7380=[""].join("\n");
var outline_f7_13_7380=null;
var title_f7_13_7381="Pemphigus vegetans";
var content_f7_13_7381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vegetans, axilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7381=[""].join("\n");
var outline_f7_13_7381=null;
var title_f7_13_7382="Bisoprolol and hydrochlorothiazide: Patient drug information";
var content_f7_13_7382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bisoprolol and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/28/26055?source=see_link\">",
"     see \"Bisoprolol and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ziac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ziac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bisoprolol, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad kidney disease, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11361 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7382=[""].join("\n");
var outline_f7_13_7382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141715\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141716\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017348\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017350\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017349\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017354\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017355\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017357\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017352\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017353\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017358\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017359\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/28/26055?source=related_link\">",
"      Bisoprolol and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7383="Natural history of asthma";
var content_f7_13_7383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Augusto A Litonjua, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Scott T Weiss, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7383/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/13/7383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of asthma is not well described. The relatively few cohort studies that initially examined this issue from childhood to early adulthood contained methodologic problems pertaining to subject selection (most were hospital or clinic based) and design (many were retrospective, did not incorporate a physiologic test for airway reactivity, and some did not examine the question of atopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/1\">",
"     1",
"    </a>",
"    ]. Within the past few years, however, more data have become available from ongoing, prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children experience complete remission more frequently than adults; however, progression to severe disease is unusual in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Although deaths do occur from asthma, asthma in the absence of other comorbid disease does not typically affect life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of asthma from infancy to adulthood will be discussed here. The diagnosis and management of asthma are presented separately. (See appropriate topic reviews). The impact of inhaled glucocorticoid treatment on the progression of childhood asthma and the role of risk factors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFANTS AND CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many infants wheeze early in life. Those who develop wheezing with lower respiratory tract illnesses have reduced lung function prior to developing any symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/8\">",
"     8",
"    </a>",
"    ]. They may, for example, have smaller airways, which predispose them to wheezing in the face of viral infections or other insults. It is not clear which factors determine the development of asthma later in life, although some possible risk factors have been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"     \"Wheezing illnesses other than asthma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Wheezing during the first six years",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the natural history of wheezing and asthma in the first six years of life.",
"   </p>",
"   <p>",
"    In one study, 826 children were assigned to four categories according to their history of wheezing at three years and at six years of age: children who never wheezed; those with transient early wheezing; those with late-onset wheezing; and those with persistent wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sixty percent of children with wheezing in the first three years of life had no wheezing at six years of age. This group of transient early wheezers was distinguished from the other groups by their low pulmonary function (assessed by maximal expiratory flow at FRC) both shortly after birth and at six years of age, even though they had \"outgrown\" their wheezing. The transient early wheezing and lower pulmonary function are likely due to smaller airways.",
"   </p>",
"   <p>",
"    In contrast, children with persistent wheezing had lung function values shortly after birth that were not different from those who never wheezed. However, they had the lowest level of lung function and the highest frequency of carrying a diagnosis of asthma (46 percent) among all groups at six years.",
"   </p>",
"   <p>",
"    Risk factors for persistent wheezing and a predisposition to asthma in this population included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent symptoms in the first year of life",
"     </li>",
"     <li>",
"      Eczema",
"     </li>",
"     <li>",
"      Elevated IgE levels",
"     </li>",
"     <li>",
"      Maternal history of asthma",
"     </li>",
"     <li>",
"      Maternal smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second study, from the same group of researchers, reported results from another cohort of children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/10\">",
"     10",
"    </a>",
"    ]. A total of 786 children younger than 5 years of age were enrolled between 1972 and 1984. The predictive power of various lower respiratory tract symptoms such as frequent cough, wheeze with and without colds, attacks of shortness of breath with wheeze (SOBWZ), chest colds, and a combination of cough, wheeze even without colds, or SOBWZ was assessed in relation to a subsequent diagnosis of asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No single lower respiratory tract symptom before the age of one year was predictive of a diagnosis of asthma at a later age.",
"     </li>",
"     <li>",
"      In logistic regression analyses, children with respiratory symptoms at 1-2 years but no respiratory symptoms at three to four years did not have a significantly increased risk for a new diagnosis of asthma between the ages of 5 and 11 years (OR=1.7, 95% CI 0.5-6.0).",
"     </li>",
"     <li>",
"      In contrast, those with lower respiratory symptoms at three to four years but without symptoms at 1-2 years, and those with symptoms at both early age groups (ie, the groups with either late-onset symptoms or persistent symptoms), had increased risk for a new diagnosis of asthma between ages 5 and 11 years (OR=9.2, 95% CI 3.2-26.2 and OR=6.6, 95% CI 2.6-17.0 respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two studies, and others, support the concept that there are at least two groups of children who have wheeze and asthma-like symptoms at an early age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. One group tends to have intermittent symptoms at an early age, usually in relation to viral illnesses, and to outgrow the symptoms as the children get older. The other group, which tends to have later-onset and more persistent symptoms, is characterized by atopy and a positive family history of asthma, and is at an increased risk for asthma later in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Wheezing in later childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that between 30 and 70 percent of children who develop asthma are markedly improved or asymptomatic by early adulthood. Several studies have examined whether certain asthma characteristics during childhood predict the presence and severity of disease decades later [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/4,14-17\">",
"     4,14-17",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    A retrospective cohort study of more than 13,000 newly diagnosed asthmatics, ranging in age from 5 to 44 years, used medication records to track the progression of disease over five years. Nearly half of these patients had mild asthma, while only 7 percent presented with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/4\">",
"     4",
"    </a>",
"    ]. When stratified by age, the following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients younger than 15 years who were diagnosed with severe asthma had, when compared to older patients, significantly higher five-year rates of improvement (80 versus 61 percent) and remission (23 versus 14 percent).",
"     </li>",
"     <li>",
"      Patients diagnosed with mild disease were unlikely to develop severe disease within five years, regardless of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate series of studies evaluated a cohort of 317 children with a history of wheezing to age 42, and compared them with 86 age-matched control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The prognosis depended upon the frequency of symptoms during childhood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      86 percent of those with few symptoms at 7 years of age continued to have little or no asthma.",
"     </li>",
"     <li>",
"      71 percent of those with frequent wheezing at 7 years still suffered from recurrent bouts of asthma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A four year study prospectively monitored 909 children who had been enrolled in the Childhood Asthma Management Program (CAMP) at ages 5 to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/17\">",
"     17",
"    </a>",
"    ]. Predictors of persistent asthma included atopy, low lung function, and higher airway hyperresponsiveness. Sensitization and exposure to indoor allergens were associated with a three times the risk of persistent asthma. More severe asthma at study enrollment was associated with more severe asthma after four years of follow up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different reports have evaluated the effects of asthma on lung function in different age groups and genders. Asthma appears to have different deleterious effects on the lung function of boys and girls, and findings vary with age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We studied a cohort of children from East Boston, aged five to nine years, over a 13-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/18\">",
"       18",
"      </a>",
"      ]. Boys with asthma experienced a larger increase in vital capacity than nonasthmatic boys, whereas in girls, the differences from normal were reflected in consistently lower forced expiratory volume in one second (FEV1) values.",
"     </li>",
"     <li>",
"      The Childhood Asthma Management Program (CAMP) followed the lung function of 1041 children (420 girls and 621 boys) with mild to moderate persistent asthma, and compared it with lung function of 5415 non-asthmatic children from the Harvard Six Cities Study [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/19\">",
"       19",
"      </a>",
"      ]. In both boys and girls between the ages of 6 and 18 years, the",
"      <span class=\"nowrap\">",
"       FEV1/",
"      </span>",
"      forced vital capacity (FVC) ratio was significantly lower and FVC was significantly greater for asthmatic children, compared to non-asthmatic children. In contrast to the East Boston study, boys had lower FEV1 between the ages of 10 to 18, whereas the differences in girls were not significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these results indicate that among children who develop asthma early in life (by age six), the",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio is lower, the FVC is greater, and FEV1 in boys is lower than that in non-asthmatics. In more general terms, these studies confirm that asthma in early childhood results in decrements in pulmonary function that are persistent and detectable in later childhood and adolescence.",
"   </p>",
"   <p>",
"    Asthma in childhood continues to influence pulmonary function later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. As an example, pulmonary function studies were performed in a cohort of children with asthma who were followed from age seven until age 28 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Children were assigned to either a control group or to one of four asthma groups based upon the severity of their symptoms. The children with the most severe symptoms had persistently lower FEV1,",
"    <span class=\"nowrap\">",
"     FEV1/FVC,",
"    </span>",
"    and FEF25-75 values as adults than the control group. Vital capacity, as a percent of predicted, was greater in this group than in controls at 14 and 21 years, although not at 28 years of age. These reports did not examine gender differences in lung function.",
"   </p>",
"   <p>",
"    Similar results were noted in a cross-sectional community-based study of respiratory symptoms in over 2500 children initiated in 1964 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/24\">",
"     24",
"    </a>",
"    ]. Long-term follow-up of a subset of this population noted that, when adjusted for age, height, gender, and smoking status, adults with childhood asthma had diminished lung function compared to nonasthmatic controls (FEV1 2.45 versus 2.96 L) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, the rate of decline in FEV1 was significantly greater for individuals with a history of asthma in childhood than for control subjects (-0.75 versus -0.59 L per year).",
"   </p>",
"   <p>",
"    Gender influences airway responsiveness, in addition to its influence on lung function tests. Among children with mild to moderate asthma followed in the CAMP trial described above, airway responsiveness increased after puberty in girls, but decreased after puberty in boys, independent of baseline FEV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of asthma correlates with the degree of impairment in lung function. Baseline data from 1041 children with mild to moderate asthma in the CAMP study found a significant correlation between asthma duration and lower lung function, greater",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    responsiveness, more asthma symptoms, and greater use of as-needed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of asthma in adults has been examined in a few studies. Adults are less likely than children to experience a complete remission from asthmatic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, the risk of progressive clinical deterioration is small, and asthma in the absence of other comorbidities does not appear to decrease life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     New onset asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristics of adults who have a new diagnosis of asthma at age 22 years were examined as part of a longitudinal study of asthma (Tucson Children's Respiratory Study) that followed 1246 healthy newborns for 22 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/13\">",
"     13",
"    </a>",
"    ]. Although subjects with new onset asthma at age 22 had no prior clinician diagnosis of asthma, 37 percent had reported wheezing during study visits in childhood and 19 percent had bronchial hyperresponsiveness by cold air bronchoprovocation at age 6. These observations suggest that \"new onset\" asthma in young adulthood may have its origin in childhood.",
"   </p>",
"   <p>",
"    Gender also appears to play a role in the age of onset of asthma, although the mechanism is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/26\">",
"     26",
"    </a>",
"    ]. In the Tucson Children's Respiratory Study, newly diagnosed asthma at age 22 was twice as likely in women compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptoms and progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the retrospective, medication-based cohort study of 13,000 newly diagnosed asthmatics described above, patients who did not receive intensive asthma therapy within a year of diagnosis were unlikely to progress clinically over the next five years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/4\">",
"     4",
"    </a>",
"    ]. Only 3 percent of patients diagnosed at age 15 or older with mild disease required treatment for severe disease at five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=see_link\">",
"     \"Diagnosis of wheezing illnesses other than asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar results were noted in a follow up-study of 738 incoming college students who were initially evaluated by interview, physical examination, skin testing, and questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/29\">",
"     29",
"    </a>",
"    ]. When contacted 23 years later, 84 alumnae with a history of asthma (48 since college entrance) completed symptom questionnaires, and the following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      40 (48 percent) were asymptomatic at follow-up, most of whom had been asymptomatic for more than 5 years.",
"     </li>",
"     <li>",
"      44 (52 percent) had ongoing symptoms of asthma. Within this group, 22 noted decreasing severity, 18 were unchanged, and only 4 experienced progression.",
"     </li>",
"     <li>",
"      The risk of developing asthma during this 23 year interval was small. Only 36 of 738 respondents (5.2 percent) reported a new diagnosis of asthma, corresponding to an incidence of 0.23 percent per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report evaluated a longitudinal sample of asthmatic adults with asthma followed since childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/14\">",
"     14",
"    </a>",
"    ]. At least in early adulthood, the severity of asthma, as judged by the frequency of symptoms, remained stable. Thus, those with frequent and severe asthma symptoms as young adults continued to have the same level of severity as they grow older. It remains to be seen whether earlier use of inhaled glucocorticoids or other newer modalities of therapy can alter the natural history of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effect on lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway hyperresponsiveness is a central feature of the definition of asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19653?source=see_link\">",
"     \"Epidemiology of asthma\"",
"    </a>",
"    .) Early studies showed that subjects with airway hyperresponsiveness had a more rapid decline in lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/1\">",
"     1",
"    </a>",
"    ]. This analysis was performed without adjustment for the initial level of lung function; as a result, the apparent relation between airway hyperresponsiveness and prognosis could actually reflect an association between a lower initial level of lung function and worse prognosis.",
"   </p>",
"   <p>",
"    However, the rate of loss of lung function does appear to be greater in patients with asthma in general, in those with more severe symptoms, and in new asthmatics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longitudinal studies have shown that patients with diagnosed asthma have a more rapid decline in lung function than nonasthmatics. In one report, for example, 92 asthmatics were compared to normal subjects using data collected over 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/31\">",
"       31",
"      </a>",
"      ]. The asthmatic subjects had a greater rate of decline in lung function. This effect appeared to be most pronounced in smoking asthmatics; however, statistical significance was not achieved due to very small numbers.",
"     </li>",
"     <li>",
"      The rate of loss of lung function may also be related to the severity of symptoms. In a study of young adults between the ages of 21 and 28 years, those with the most severe symptoms had the most rapid rate of decline in the",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      ratio compared to controls and patients with less severe asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rate of decline in lung function may be greatest in new asthmatics. One group studied 10,952 persons who were part of an ongoing longitudinal study, The Copenhagen City Heart Study, to analyze the rate of decline in lung function of adults with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/32\">",
"       32",
"      </a>",
"      ]. Over a five year period, 159 subjects were identified who were self-reported asthmatics at initial study and follow-up and 185 subjects who reported no asthma on initial encounter but developed asthma during the study. The new asthmatics had the largest loss of lung function; the excess decline, on average, was 39",
"      <span class=\"nowrap\">",
"       mL/year",
"      </span>",
"      in men and 11",
"      <span class=\"nowrap\">",
"       mL/year",
"      </span>",
"      in women when compared with declines in nonasthmatics. After controlling for the initial level of FEV1, subjects with chronic asthma had rates of decline that were different than those in nonasthmatics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent report of 15 years of follow-up data from the same group, the more rapid decline in lung function of asthmatics was confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/33\">",
"     33",
"    </a>",
"    ]. The decline in FEV1 among subjects with asthma was 38 mL per year, compared with 22 mL per year in those without asthma. Asthmatics who smoked had the greatest rates of lung function decline compared with nonasthmatics and nonsmoking asthmatics.",
"   </p>",
"   <p>",
"    Another study of adults greater than 60 years of age also noted a rapid fall in lung function around the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/34\">",
"     34",
"    </a>",
"    ]. Rates of decline in FEV1 were almost twice as high in subjects with newly diagnosed asthma as in other subjects. This phenomenon may reflect the fact that the decline in lung function was what led the patients to seek medical attention. Alternatively, it may reflect submaximal therapy, although it is uncertain that optimal treatment can modify the rapid rates of decline in asthmatics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=see_link\">",
"     \"Diagnosis and management of asthma in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENTS WITH SEVERE ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information about the natural history of severe asthma or difficult-to-control asthma. The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study was a three-year multicenter observational study of 4756 patients six years of age and older with severe or difficult-to-control asthma, designed to gather preliminary information about the clinical course of asthma in this subset of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/28,35,36\">",
"     28,35,36",
"    </a>",
"    ]. Patients were managed by specialists (pulmonologists or allergists) although there was no experimental intervention. Heavy smokers and patients with other concomitant lung diseases were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Participants met one or both of the following criteria in the year before the study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High health care utilization (as defined as two or more unscheduled visits for asthma or two or more courses of oral glucocorticoids)",
"     </li>",
"     <li>",
"      High medication use (eg, requiring three or more medications to control asthma, long-term daily use of high dose inhaled glucocorticoids, or use of 5 mg daily or more of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seventy-three percent of the group were adults; 26 percent were children or adolescents 6 to 17 years of age. Between 50 and 60 percent of patients were receiving three or more long-term controller medications. Despite this, 40 to 50 percent required courses of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and unscheduled visits within the three months prior to interview, indicating that symptoms were not controlled in many. Pulmonary function declined with age, particularly in adolescent boys [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7383/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The studies reported above suggest the following conclusions concerning the natural history of asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wheezing in young children is a heterogeneous condition characterized by relatively low pre-illness lung function compared to that in normal children. For most children, wheezing before the age of six years is probably a benign condition reflecting smaller airways that will improve or resolve in a few years.",
"     </li>",
"     <li>",
"      A subgroup will have persistence of symptoms and will eventually develop clinical asthma. This subgroup is characterized by the atopic state, relatively severe and persistent symptoms at a young age, and a maternal history of asthma. Maternal smoking may also contribute.",
"     </li>",
"     <li>",
"      Wheezing and asthma in adolescence is associated with a high rate of persistence into adulthood; however, progressive worsening over time is unusual.",
"     </li>",
"     <li>",
"      Children with more severe symptoms also have lower lung function than those with less severe symptoms; this relationship persists into early adult life. The implications of this observation for adult lung disease need further study.",
"     </li>",
"     <li>",
"      Adults with wheezing are more likely than children to experience persistent asthma and loss of lung function.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Weiss ST, Speizer FE. Epidemiology and natural history. In: Bronchial Asthma Mechanisms and Therapeutics, 3rd, Weiss EB, Stein M (Eds), Little, Brown, Boston 1993. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/2\">",
"      Guilbert T, Krawiec M. Natural history of asthma. Pediatr Clin North Am 2003; 50:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/3\">",
"      Bisgaard H, B&oslash;nnelykke K. Long-term studies of the natural history of asthma in childhood. J Allergy Clin Immunol 2010; 126:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/4\">",
"      Ernst P, Cai B, Blais L, Suissa S. The early course of newly diagnosed asthma. Am J Med 2002; 112:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/5\">",
"      Bronnimann S, Burrows B. A prospective study of the natural history of asthma. Remission and relapse rates. Chest 1986; 90:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/6\">",
"      Silverstein MD, Reed CE, O'Connell EJ, et al. Long-term survival of a cohort of community residents with asthma. N Engl J Med 1994; 331:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/7\">",
"      McFadden ER Jr. Natural history of chronic asthma and its long-term effects on pulmonary function. J Allergy Clin Immunol 2000; 105:S535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/8\">",
"      Tager IB, Hanrahan JP, Tosteson TD, et al. Lung function, pre- and post-natal smoke exposure, and wheezing in the first year of life. Am Rev Respir Dis 1993; 147:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/9\">",
"      Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/10\">",
"      Dodge R, Martinez FD, Cline MG, et al. Early childhood respiratory symptoms and the subsequent diagnosis of asthma. J Allergy Clin Immunol 1996; 98:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/11\">",
"      Vonk JM, Postma DS, Boezen HM, et al. Childhood factors associated with asthma remission after 30 year follow up. Thorax 2004; 59:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/12\">",
"      Matricardi PM, Illi S, Gr&uuml;ber C, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J 2008; 32:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/13\">",
"      Stern DA, Morgan WJ, Halonen M, et al. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet 2008; 372:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/14\">",
"      Kelly WJ, Hudson I, Phelan PD, et al. Childhood asthma in adult life: a further study at 28 years of age. Br Med J (Clin Res Ed) 1987; 294:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/15\">",
"      Oswald H, Phelan PD, Lanigan A, et al. Outcome of childhood asthma in mid-adult life. BMJ 1994; 309:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/16\">",
"      Horak E, Lanigan A, Roberts M, et al. Longitudinal study of childhood wheezy bronchitis and asthma: outcome at age 42. BMJ 2003; 326:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/17\">",
"      Covar RA, Strunk R, Zeiger RS, et al. Predictors of remitting, periodic, and persistent childhood asthma. J Allergy Clin Immunol 2010; 125:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/18\">",
"      Weiss ST, Tosteson TD, Segal MR, et al. Effects of asthma on pulmonary function in children. A longitudinal population-based study. Am Rev Respir Dis 1992; 145:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/19\">",
"      Strunk RC, Weiss ST, Yates KP, et al. Mild to moderate asthma affects lung growth in children and adolescents. J Allergy Clin Immunol 2006; 118:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/20\">",
"      Martin AJ, Landau LI, Phelan PD. Lung function in young adults who had asthma in childhood. Am Rev Respir Dis 1980; 122:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/21\">",
"      Kelly WJ, Hudson I, Raven J, et al. Childhood asthma and adult lung function. Am Rev Respir Dis 1988; 138:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/22\">",
"      Jenkins MA, Hopper JL, Bowes G, et al. Factors in childhood as predictors of asthma in adult life. BMJ 1994; 309:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/23\">",
"      Godden DJ, Ross S, Abdalla M, et al. Outcome of wheeze in childhood. Symptoms and pulmonary function 25 years later. Am J Respir Crit Care Med 1994; 149:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/24\">",
"      Dawson B, Illsley R, Horobin G, Mitchell R. A survey of childhood asthma in Aberdeen. Lancet 1969; 1:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/25\">",
"      Edwards CA, Osman LM, Godden DJ, Douglas JG. Wheezy bronchitis in childhood: a distinct clinical entity with lifelong significance? Chest 2003; 124:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/26\">",
"      Tantisira KG, Colvin R, Tonascia J, et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med 2008; 178:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/27\">",
"      Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999; 103:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/28\">",
"      Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007; 119:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/29\">",
"      Settipane GA, Greisner WA 3rd, Settipane RJ. Natural history of asthma: a 23-year followup of college students. Ann Allergy Asthma Immunol 2000; 84:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/30\">",
"      Sears MR. Consequences of long-term inflammation. The natural history of asthma. Clin Chest Med 2000; 21:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/31\">",
"      Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/32\">",
"      Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994; 150:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/33\">",
"      Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/34\">",
"      Burrows B, Lebowitz MD, Barbee RA, Cline MG. Findings before diagnoses of asthma among the elderly in a longitudinal study of a general population sample. J Allergy Clin Immunol 1991; 88:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/35\">",
"      Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7383/abstract/36\">",
"      Miller MK, Johnson C, Miller DP, et al. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116:990.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 567 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7383=[""].join("\n");
var outline_f7_13_7383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFANTS AND CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Wheezing during the first six years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Wheezing in later childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on lung function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      New onset asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptoms and progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effect on lung function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENTS WITH SEVERE ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=related_link\">",
"      Diagnosis and management of asthma in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=related_link\">",
"      Diagnosis of wheezing illnesses other than asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19653?source=related_link\">",
"      Epidemiology of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7384="Pityriasis rosea on abdomen";
var content_f7_13_7384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87124%7EDERM%2F87126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87124%7EDERM%2F87126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oval, erythematous papules and small plaques are present on the abdomen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and oval plaques are present on the trunk. A larger herald patch is on the right midback.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7384=[""].join("\n");
var outline_f7_13_7384=null;
var title_f7_13_7385="Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults";
var content_f7_13_7385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7385/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7385/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7385/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/13/7385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rheumatoid arthritis (RA) and persistently active disease despite initial pharmacologic therapies require adjustments in their treatment regimen to achieve effective disease control. The use of combinations of disease-modifying antirheumatic drugs (DMARDs) is typically required in patients with persistently active disease, defined as RA of at least six months duration, which remains active despite initial treatment with one or several DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DMARDs are divided into two broad categories: nonbiologic and biologic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nonbiologic DMARDs are traditional small-molecule or synthetic DMARDs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The biologic DMARDs, produced by recombinant DNA technology, usually target specific cytokines or their receptors, such as tumor necrosis factor (TNF)-alpha or the TNF, interleukin (IL)-1 or IL-6 receptor. Other types of biologic DMARDs include B cell depleting agents and T cell costimulatory blockers. The use of biologic DMARDs has been referred to as \"targeted therapy.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of representative clinical trials in patients with persistently active RA despite prior DMARD therapy will be reviewed here. The principles and strategies for treating such patients and randomized trials of nonbiologic DMARD combinations and of biologic agents are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=see_link\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link\">",
"     \"T cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMBINATIONS OF NONBIOLOGIC DMARDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of combinations of nonbiologic DMARDs are more effective than single agents. The following examples include some commonly prescribed combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Triple therapy with MTX-SSZ-HCQ",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination nonbiologic DMARDs were evaluated in a randomized trial of 102 patients with established RA, disease lasting more than six months, and a poor response to one DMARD or to two or more sequential DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/2\">",
"     2",
"    </a>",
"    ]. Triple therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX, 7.5 to 17.5 mg per week, titrated for response),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ, 500 mg twice daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ, 200 mg twice daily) was superior to SSZ plus HCQ or to MTX alone in achieving the primary end point of at least a 50 percent improvement at nine months (77 versus 40 and 33 percent, respectively), with sustained benefit for at least two years without the development of significant drug toxicity.",
"   </p>",
"   <p>",
"    Additional support for the efficacy of a similar regimen was provided by a randomized trial in DMARD-naive patients who had RA for less than two years and persistent disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/3\">",
"     3",
"    </a>",
"    ]. The patients were treated with MTX, SSZ, and HCQ or with SSZ with sequential switching if the clinical response was inadequate to MTX and then to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The rate of remission was significantly higher in the patients treated with triple therapy at both one year (24.7 versus 11.2 percent) and two years (37.1 versus 18.4 percent). Triple therapy was also associated with significantly higher rates or at least a 50 percent response at one year (75 versus 60 percent) and with more limited joint damage at two and five years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/4\">",
"     4",
"    </a>",
"    ]. Although treatment was unrestricted after two years, differences in radiographic damage persisted at five years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     MTX-HCQ versus MTX-SSZ versus all three",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two year trial included 171 patients with disease of more than six months duration who had not received DMARD combinations; the patients were randomly assigned to a three-drug combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX, 7.5 to 17.5 mg per week),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ. 500 mg to 1000 mg twice daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ, 200 mg twice daily) or to two-drug regimens of either MTX plus HCQ or MTX plus SSZ [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/5\">",
"     5",
"    </a>",
"    ]. The primary end point, which was the percent of patients who achieved an ACR20 response at two years, was significantly higher with the three-drug regimen (78 versus 60 and 49 percent, respectively). A similar difference was seen for ACR50 responses (55 versus 40 and 29 percent, respectively). The likelihood of a response did not appear to differ between patients who were MTX-naive and those who had previously received MTX but responded inadequately. All treatment regimens were well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     MTX-leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    (LEF) is usually used as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), but the two drugs can also be used in combination. Although both drugs are potentially hepatotoxic, the rationale for combined therapy is based upon their differing mechanisms of action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of either LEF or placebo to MTX was compared in a randomized trial of 263 patients with persistently active disease despite treatment with MTX for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/6\">",
"     6",
"    </a>",
"    ]. The results of this trial are discussed in detail elsewhere but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=see_link&amp;anchor=H11#H11\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\", section on 'Leflunomide and MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary outcome, the proportion of patients achieving an ACR20 after 24 weeks of therapy, was significantly higher in the group receiving LEF plus MTX (46.2 versus 19.5 percent). The combination was well tolerated. The rate of discontinuation and the incidence of adverse events, which were predominantly mild or moderate, were similar in the two groups. Diarrhea and elevation of serum aminotransferases were the only adverse effects seen significantly more often with LEF plus MTX than with placebo plus MTX. Close monitoring for hepatotoxicity is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     MTX-cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A six-month randomized trial evaluated the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSA) in 148 patients with severe RA; the patients were assigned to receive MTX (at the maximal tolerated dose) plus CSA (2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or MTX plus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/7\">",
"     7",
"    </a>",
"    ]. After six months of treatment, the combination of MTX and CSA resulted in a greater reduction in the tender-joint count, the primary outcome, compared with MTX plus placebo (-7.5 versus -2.7 joints). The net decrease of -4.8 joints was equal to 25 percent of the initial tender-joint count. An ACR20 response was achieved more often in the combination group (48 versus 16 percent). Clinical improvement was maintained when the study was extended for another 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were 17 patients in the CSA group and 12 in the placebo group who withdrew from the study. The threshold for CSA dose reduction was a 30 percent increase in serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     MTX-gold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injected gold salts are now used infrequently because of significant toxicity, and there is only a small proportion of patients who have long-term efficacy without serious side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=see_link\">",
"     \"Use of gold compounds in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of intramuscular (IM) gold injections to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) may benefit some patients who are unable to use other potent alternative agents. In the METGO trial, 65 patients with RA and a partial response to MTX (mean dose of 18.5",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    continued MTX and were randomly assigned to IM gold (aurothioglucose up to 50 mg once weekly as tolerated) or placebo injections for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients who received IM gold were significantly more likely to achieve the primary outcome, an ACR20 response at week 48 (61 versus 30 percent). ACR50 and ACR70 were also achieved more often with gold plus MTX (26 versus 4 percent and 21 versus 0 percent, respectively).",
"   </p>",
"   <p>",
"    Adverse events were minor. Mucocutaneous side effects were frequent, but usually required only temporary suspension of gold therapy. Gold-related adverse events led to permanent discontinuation of therapy in 11% of patients receiving gold.",
"   </p>",
"   <p>",
"    This combination is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=see_link&amp;anchor=H11#H11\">",
"     \"Use of gold compounds in rheumatic diseases\", section on 'Gold combined with other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONBIOLOGIC DMARDS PLUS ANTI-TNF THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials support the efficacy of adding an anti-tumor necrosis factor (TNF)-alpha agent to ongoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link&amp;anchor=H7011196#H7011196\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\", section on 'MTX plus TNF inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although several of the TNF-alpha inhibitors can be used as the initial DMARD and as single agents, the combination of a TNF-alpha inhibitor with MTX results in a greater likelihood of a good response to treatment and in better radiographic outcomes than either treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The following are examples of such combinations:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     MTX-etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with a TNF-alpha receptor fusion protein,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and MTX was evaluated in a trial of 89 patients with persistent disease despite at least six months of treatment with MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients were randomly assigned to twice weekly subcutaneous etanercept (25 mg) or placebo, while continuing to receive MTX. Significantly more patients in the active therapy than in the placebo group achieved an ACR 20 response, the primary outcome measure, and an ACR50 response at 24 weeks of therapy (71 versus 27 percent and 39 versus 3 percent, respectively).",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and MTX may also be more effective in retarding radiographic joint damage than either agent alone. This was illustrated in the TEMPO trial of 686 patients with active disease of over six months duration who had responded inadequately to at least one DMARD but who had not received MTX. Patients were randomly assigned to one of three regimens: a combination of etanercept (25 mg twice weekly) and MTX (up to 20",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    etanercept and placebo, or MTX and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinical and radiographic assessments were made periodically during one year of study.",
"   </p>",
"   <p>",
"    Greater improvements with the combination than either drug alone were evident in symptoms and signs of disease activity, physical function, patient reported outcomes, and radiographic data. The primary efficacy endpoint was the ACR-N, the numeric index of the ACR response area under the curve (AUC) over the first 24 weeks. The ACR-N AUC was greater for the combination group than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    alone and MTX alone (18.3 versus 14.7 versus 12.2 percent-years). The difference between etanercept alone and MTX was also significant.",
"   </p>",
"   <p>",
"    The combination also resulted in reduced radiographic joint injury compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    alone or MTX alone according to the primary radiographic endpoint, the change in the modified Sharp score at week 52 (-0.54 versus +0.52 versus +2.80).",
"   </p>",
"   <p>",
"    Results of the TEMPO trial at two years are available for 503 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/16\">",
"     16",
"    </a>",
"    ]. ACR20, ACR50, and ACR70 responses remained significantly greater, withdrawal rates lower, and radiographic progression slower in the group receiving combination therapy than either of the monotherapy groups. Similar proportions of patients had serious infections in each of the three groups (7, 6, and 6 percent).",
"   </p>",
"   <p>",
"    Doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    greater than 50 mg weekly, with or without MTX, do not appear to have greater efficacy in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This combination is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H3#H3\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Etanercept'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     MTX-infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    (an anti-TNF monoclonal antibody) is also effective in patients with persistently active disease, and is generally used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In the ATTRACT trial involving 428 patients with disease duration greater than six months (median 7.2 to 9.0 years) and active disease despite receiving MTX for at least three months, infliximab plus MTX was superior to placebo plus MTX in controlling signs and symptoms of disease and improving physical function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients on one of the four",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    plus MTX regimens were more likely to reach the primary outcome, an ACR20 response at 30 weeks of treatment (50 to 58 versus 20 percent). These benefits were maintained for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/21\">",
"     21",
"    </a>",
"    ]. Similar numbers of serious adverse events, including serious infections, were seen in infliximab and placebo treated patients.",
"   </p>",
"   <p>",
"    In the ASPIRE trial, combination therapy with MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    provided greater clinical, radiographic, and functional benefits than MTX plus placebo for patients with active, early RA (3 to 36 months duration, mean of 10.4 months) who were not previously exposed to MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/22\">",
"     22",
"    </a>",
"    ]. The primary endpoint for clinical efficacy, the ACR-N, which represents percent improvement in signs and symptoms, was significantly higher in patients on infliximab (3 or 6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus MTX (38.9 and 46.7 versus 26.4 percent). Similarly, the infliximab patients exhibited less radiographic progression of joint damage as measured by the primary radiographic endpoint, the van der Heijde modified Sharp score (vdH-S), (vdH-S of 0.4 and 0.5 versus 3.7). There was a higher incidence of serious infections with combination therapy (5.0 to 5.6 versus 2.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients initially controlled with a given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    dosing regimen may subsequently require higher infliximab doses or a decrease in the dosing interval to continue to suppress disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This combination is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H4#H4\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Infliximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     MTX-adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of the addition of the fully human anti-TNF-alpha monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , to ongoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) therapy was demonstrated in the ARMADA trial of 271 patients with active RA despite treatment with MTX for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/24\">",
"     24",
"    </a>",
"    ]. In this 52-week randomized trial, the addition to MTX of adalimumab given subcutaneously at a dose of either 20, 40, or 80 mg every two weeks was more effective than placebo for achieving the primary efficacy endpoint, the proportion of patients with an ACR20 response (47.8, 67.2, and 65.8 versus 14.5 percent). Adverse events were comparable between adalimumab and placebo treated patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    exhibited radiographic, clinical, and functional benefits in a trial of 619 patients with active RA despite ongoing treatment with MTX for &ge; 3 months and at least one joint erosion on radiographs of the hands and feet [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/25\">",
"     25",
"    </a>",
"    ]. In this study, patients were randomized to receive either adalimumab (40 or 20 mg subcutaneously every 2 weeks) plus MTX or placebo plus MTX.",
"   </p>",
"   <p>",
"    The primary efficacy endpoints were: radiographic progression of structural joint damage at week 52, assessed by the modified total Sharp score (mTSS); clinical response at week 24, measured by the proportion of patients with an ACR20 response; and physical function at week 52, measured with the disability index of the Health Assessment Questionnaire (HAQ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    patients achieved a significantly lower mTSS (0.1 and 0.8 versus 2.7), higher proportion of patients with an ACR20 (63 and 61 versus 30 percent), and greater decreases in the HAQ score (-0.59 and -0.61 versus -0.25).",
"   </p>",
"   <p>",
"    The serious and nonserious adverse event rates were comparable in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and placebo groups, but serious infections were reported more often with adalimumab (3.8 versus 0.5 percent).",
"   </p>",
"   <p>",
"    Additional support for this combination is demonstrated by the PREMIER trial of patients with active RA for less than three years (57% for &lt; 6 months) not previously exposed to MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/26\">",
"     26",
"    </a>",
"    ]. Combination therapy with MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was more effective than either drug alone in improving signs and symptoms of disease, inhibiting radiographic progression, and affecting clinical remission.",
"   </p>",
"   <p>",
"    This combination is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     MTX-golimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    , a TNF inhibitor that is administered by monthly subcutaneous injection, demonstrated benefit in the GO-FORWARD study when given together with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) in patients who had not responded adequately to at least 3 months of treatment with MTX alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the GO-FORWARD trial, patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    (100 or 50 mg) plus MTX were more likely to achieve an ACR20 response at week 14, one of two primary outcomes, than patients on either golimumab (100 mg) or MTX alone (56 and 55 versus 44 versus 33 percent). The other primary outcome, which was the degree of improvement in physical function measured using the Health Assessment Questionnaire Disability Index (HAQ-DI), showed similar superiority for the golimumab plus MTX combinations (-0.50 and -0.38 versus -0.13 versus -0.13).",
"   </p>",
"   <p>",
"    In",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    plus MTX treated patients, an ACR50 and ACR70 were also reached more often at week 14 (29 and 35 versus 20 versus 10 percent and 14 and 9 versus 8 versus 4 percent, respectively). DAS28 remissions were more common as well (18 and 16 versus 8 versus 2 percent).",
"   </p>",
"   <p>",
"    Serious adverse events through week 16 in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    (100 or 50 mg) plus MTX, golimumab plus placebo, or MTX plus placebo occurred in 9.0, 5.6, 3.8 and 2.3 percent of patients. Serious infections occurred in 5.6, 2.2, 0.8, and 0.8 percent of patients, respectively. Latent tuberculosis was detected at screening and treated in 21 percent of patients. None of these patients developed active tuberculosis during the study, nor were opportunistic infections seen in any of the study patients.",
"   </p>",
"   <p>",
"    Injection site reactions were uncommon (&lt; 5 percent) and mild. The 2.1 percent of patients with antibodies to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    at week 24 had all initially received golimumab alone without MTX for the first 16 weeks of the study.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    in patients with active RA despite prior use of at least one TNF inhibitor was described in a preliminary report of a trial of 461 patients who were randomly assigned to receive golimumab (50 or 100 mg every four weeks) or placebo, while continuing baseline nonbiologic DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/28\">",
"     28",
"    </a>",
"    ]. Among the patients in whom prior TNF inhibitor therapy was discontinued for lack of efficacy, those treated with golimumab were significantly more likely to achieve an ACR20 at week 14 (36 and 43 versus 18 percent). There were no significant differences in serious adverse events or serious infections between the groups.",
"   </p>",
"   <p>",
"    This combination is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     MTX-certolizumab pegol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    (CZP), which is administered by subcutaneous injection every 2 weeks, improves signs and symptoms of RA in patients with active disease despite at least 2 months of treatment with MTX (&ge; 10",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/29\">",
"     29",
"    </a>",
"    ]. In the RAPID 1 trial 982 patients on MTX were randomized to receive CZP (400 mg at weeks 0, 2, and 4, followed by either 200 or 400 mg every 2 weeks) or placebo.",
"   </p>",
"   <p>",
"    ACR20 responder rates at week 24, one of the primary outcomes, were greater for patients who received CZP (200 or 400 mg) plus MTX than placebo plus MTX (59 and 61 versus 14 percent). At week 52, mean radiographic progression from baseline (change in mTSS), the other primary outcome, was significantly lower in the CZP treated patients (+0.4 and +0.2 versus +2.8).",
"   </p>",
"   <p>",
"    Efficacy was evident at week 1, by which time CZP treated patients were more likely to have achieved an ACR20 response (23 and 22 versus 6 percent). At week 24, patients treated with CZP were more likely to achieve an ACR50 (37 and 40 versus 8 percent) or ACR70 (21 and 21 versus 3 percent).",
"   </p>",
"   <p>",
"    Improvement in physical function was also evident in the CZP treated patients at week 1 (HAQ-DI mean change of -13.5 and -10.9 versus -2.4) and was sustained through week 52 (-0.60 and -0.63 versus -0.18).",
"   </p>",
"   <p>",
"    The rates of serious adverse events and serious infections in the two CZP plus MTX groups and the placebo plus MTX patients were 15.2, 14.8, and 12.0 per 100 patient-years and 7.3, 5.3, and 2.2 per 100 patient-years, respectively. The most common serious infections reported were pneumonia, gastroenteritis, urinary tract infections, and tuberculosis. Tuberculosis was seen in five patients from Eastern Europe, but none from North America. These included three patients with negative chest radiographs and positive tuberculin skin tests who had received past BCG vaccination, and one individual who worked in a tuberculosis clinic.",
"   </p>",
"   <p>",
"    Anti-CZP antibodies were detected in 6.4 percent of patients receiving CZP at week 52.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leflunomide-TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF) has been used in combination with tumor necrosis factor (TNF)-alpha inhibitors, but is much less well studied. An observational study using a population based RA cohort of 1218 patients showed no difference between patients who received a TNF inhibitor with either methotrexate, leflunomide, or another nonbiologic DMARD in discontinuation rates, radiographic damage, functional disability, disease activity or adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     TNF inhibitor switching",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inadequate response to one anti-TNF agent is not predictive of resistance to other agents in this class. Observations that provide support for the efficacy of switching and some estimate of its benefit are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link&amp;anchor=H8152910#H8152910\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\", section on 'Resistant to one TNF inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MTX PLUS T CELL COSTIMULATION BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    inhibits T cell costimulation and is effective in the treatment RA as monotherapy and in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . It has also been effective in patients who have not adequately responded to the combination of methotrexate with a tumor necrosis factor inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link&amp;anchor=H3#H3\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Costimulatory molecule inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MTX PLUS IL-1 OR IL-6 INHIBITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     MTX-anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of the recombinant human interleukin-1 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , was effective when added to a stable dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in patients with moderate to severe RA in a 24-week trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/31\">",
"     31",
"    </a>",
"    ]. Although additional studies have also shown benefit, anakinra is now rarely used in RA because it is significantly less potent than TNF inhibitors in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link&amp;anchor=H3#H3\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Anakinra'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'Anakinra'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     MTX-tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    , a humanized anti-IL-6 receptor antibody, is effective when used together with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in patients who have had an inadequate response to methotrexate (MTX) alone or to MTX used together with a tumor necrosis factor inhibitor. Clinical trials of tocilizumab are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link&amp;anchor=H5#H5\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Tocilizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RITUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;B lymphocyte depletion using a monoclonal antibody to CD20 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) has been assessed in various clinical trials. &nbsp;Initial studies that enrolled patients with severe RA that was refractory to DMARD therapy used rituximab in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and high doses of glucocorticoids. Less complex regimens without cyclophosphamide and limiting glucocorticoid use were also found to be clinically efficacious. A detailed discussion of clinical trials of rituximab is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     MTX-rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;B lymphocyte depletion using a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been effective in randomized trials of patients resistant to methotrexate alone as well as those resistant to TNF inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7385/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. &nbsp;Preliminary data from long-term safety follow-up studies suggest a similar safety profile to other biologics. However, concerns regarding rare reports of PML with rituximab have resulted in use of this combination primarily in patients in whom TNF inhibitors have been inadequate. Further, rituximab was found to be more effective in patients who are seropositive for rheumatoid factor or anti-CCP antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1135140\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with rheumatoid arthritis (RA) and persistently active disease despite initial pharmacologic therapies require adjustments in their treatment regimen to achieve effective disease control. The use of combinations of disease-modifying antirheumatic drugs (DMARDs), which may include both nonbiologic (traditional) and biologic DMARDs, is typically required in patients with persistently active disease, (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of combinations of nonbiologic DMARDs are more effective than such agents when used alone. Beneficial combinations include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ), also termed &ldquo;triple therapy&rdquo;; MTX plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      (LEF), used with particular caution because of the risk of hepatotoxicity with either drug; and to a lesser degree than triple therapy, MTX plus either HCQ or SSZ. The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (CYS) or parenteral gold to MTX has also been studied, but these combinations are used very infrequently because of potential toxicities of CYS and gold. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Combinations of nonbiologic DMARDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Triple therapy with MTX-SSZ-HCQ'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'MTX-HCQ versus MTX-SSZ versus all three'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'MTX-leflunomide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'MTX-cyclosporine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'MTX-gold'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials support the efficacy of adding an anti-tumor necrosis factor (TNF)-alpha agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      ) to ongoing MTX therapy, resulting in a greater likelihood of a good response to treatment and in better radiographic outcomes than either treatment alone. A strategy that is less well studied is the combination of LEF with a TNF inhibitor. An inadequate response to one anti-TNF agent is not predictive of resistance to other agents in this class. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonbiologic DMARDs plus anti-TNF therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'MTX-etanercept'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'MTX-infliximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'MTX-adalimumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'MTX-golimumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'MTX-certolizumab pegol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Leflunomide-TNF inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'TNF inhibitor switching'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combinations of MTX with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      , a T cell costimulation blocker, or with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      , a humanized anti-IL-6 receptor antibody, are also effective in patients with persistent disease activity. Some benefit has been shown with the combination of MTX and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      , a recombinant human IL-1 receptor antagonist, but this combination is used very infrequently because of the greater efficacy observed with use of TNF inhibitors compared with anakinra. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'MTX plus T cell costimulation blockade'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'MTX plus IL-1 or IL-6 inhibition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'MTX-anakinra'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'MTX-tocilizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B lymphocyte depletion using a monoclonal antibody to CD20 (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) has been assessed in various clinical trials. The combination of rituximab plus MTX has been effective in randomized trials of patients resistant to MTX alone as well as those resistant to TNF inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"       \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H20\">",
"       'Rituximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'MTX-rituximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/1\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/2\">",
"      O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/3\">",
"      M&ouml;tt&ouml;nen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/4\">",
"      Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/5\">",
"      O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/6\">",
"      Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/7\">",
"      Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/8\">",
"      Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997; 40:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/9\">",
"      Lehman AJ, Esdaile JM, Klinkhoff AV, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005; 52:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/10\">",
"      Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/11\">",
"      van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/12\">",
"      Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/13\">",
"      Lee YH, Woo JH, Rho YH, et al. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/14\">",
"      Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/15\">",
"      Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/16\">",
"      van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/17\">",
"      Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006; 33:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/18\">",
"      Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/19\">",
"      Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/20\">",
"      Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/21\">",
"      Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/22\">",
"      St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/23\">",
"      Ariza-Ariza R, Navarro-Sarabia F, Hern&aacute;ndez-Cruz B, et al. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/24\">",
"      Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/25\">",
"      Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/26\">",
"      Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/27\">",
"      Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/28\">",
"      Smolen J, Kay J, Doyle MK, et al. Golimumab, a new human anti-TNF alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF alpha agent(s): results of the randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2008; 67(Suppl 2):50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/29\">",
"      Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58:3319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/30\">",
"      Finckh A, Dehler S, Gabay C, SCQM doctors. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009; 68:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/31\">",
"      Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/32\">",
"      Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD005121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/33\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7385/abstract/34\">",
"      Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7495 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7385=[""].join("\n");
var outline_f7_13_7385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1135140\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMBINATIONS OF NONBIOLOGIC DMARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Triple therapy with MTX-SSZ-HCQ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MTX-HCQ versus MTX-SSZ versus all three",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MTX-leflunomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MTX-cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MTX-gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONBIOLOGIC DMARDS PLUS ANTI-TNF THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MTX-etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MTX-infliximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MTX-adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MTX-golimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MTX-certolizumab pegol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leflunomide-TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TNF inhibitor switching",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MTX PLUS T CELL COSTIMULATION BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MTX PLUS IL-1 OR IL-6 INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MTX-anakinra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MTX-tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RITUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MTX-rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1135140\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=related_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=related_link\">",
"      Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25319?source=related_link\">",
"      Use of gold compounds in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7386="Genetic and environmental causes of birth defects";
var content_f7_13_7386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic and environmental causes of birth defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7386/contributors\">",
"     Harry Ostrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7386/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/13/7386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/13/7386/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/13/7386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major birth defect is one of medical, surgical or cosmetic significance. The prevalence of these defects is 2 to 4 percent among live born infants and does not vary among ethnic groups (",
"    <a class=\"graphic graphic_table graphicRef79937 \" href=\"UTD.htm?35/15/36092\">",
"     table 1",
"    </a>",
"    ). Birth defects may be isolated or multiple and can affect one or more organ systems. Both genetic and environmental factors play a role in their pathogenesis. As an example, parents with a birth defect, a previously affected child, or a family history of birth defects are at higher risk of having a baby with the same, or a different, anomaly. Other risk factors include maternal age, illness, drug use, exposure to infectious or environmental agents, and the physical features of the intrauterine environment.",
"   </p>",
"   <p>",
"    The relative contribution of various etiologies to the overall frequency of birth defects is estimated to be [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unknown cause, including suspected polygenic and multifactorial causes (65 to 75 percent)",
"     </li>",
"     <li>",
"      Genetic: single gene disorders (15 to 20 percent), chromosomal abnormalities (5 percent)",
"     </li>",
"     <li>",
"      Environmental exposures (eg, maternal medical conditions, substance abuse, infection, drugs, chemicals, radiation, hyperthermia; mechanical constraints on fetal development) (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMMON FEATURES OF CHROMOSOMAL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are certain common characteristics of the syndromes that are produced by constitutional chromosomal abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater than 90 percent of",
"      <span class=\"nowrap\">",
"       embryos/fetuses",
"      </span>",
"      with constitutional chromosomal abnormalities do not survive to term. In trisomy 21, as an example, 40 percent of fetuses are lost after 12 weeks of gestation. Even higher embryonic and fetal loss rates are found with monosomy X.",
"     </li>",
"     <li>",
"      Multiple organ systems tend to be involved, especially the central nervous system. Intellectual disability, in particular, is a common abnormality in viable infants.",
"     </li>",
"     <li>",
"      The longevity and fertility of individuals with these conditions tend to be reduced. As an example, the risk of malignancy is increased for certain chromosomal disorders, such as trisomy 21, deletions of the long arm of chromosome 13; deletions of the short arm of chromosome 11, and 46,XY gonadal dysgenesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STRUCTURAL CHROMOSOMAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal abnormalities affect approximately 1 in 200 newborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These defects may be either sporadic or heritable and are due to a number of different etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=see_link\">",
"     \"Basic principles of genetic counseling for the obstetrical provider\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"     \"Basic principles of genetic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nondisjunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sporadic chromosomal abnormalities result from loss or gain of a chromosome, usually from nondisjunction. Nondisjunction refers to the process whereby paired chromosomes fail to separate during cell division so that both chromosomes go to one daughter cell and none to the other. Thus, after fertilization, one daughter cell inherits three chromosomes of the affected chromosome and becomes trisomic (eg, trisomy 21 or Down syndrome), while the other daughter cell inherits only one chromosome resulting in monosomy (",
"    <a class=\"graphic graphic_figure graphicRef51363 \" href=\"UTD.htm?27/11/27825\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81597 \" href=\"UTD.htm?33/16/34051\">",
"     figure 2",
"    </a>",
"    ). Cytogenetic surveys of spontaneous abortions during the first trimester of pregnancy demonstrated that approximately one-half were associated with trisomic or monosomic abortuses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trisomic embryos have been described for almost all of the autosomes. Some trisomies (eg, trisomy 13, 18, 21, and those involving the sex chromosomes) can result in live births [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/6\">",
"     6",
"    </a>",
"    ], while others (eg, trisomy 16) are detected only in abortuses. The risk of trisomy of the autosomal and sex chromosomes increases with maternal age, but the magnitude of this risk varies somewhat depending on the chromosome (",
"    <a class=\"graphic graphic_table graphicRef75423 \" href=\"UTD.htm?16/60/17357\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The incidence of monosomy X (Turner syndrome) does not increase with maternal age.",
"   </p>",
"   <p>",
"    The extra chromosome of a trisomic group is maternal in origin in the vast majority of cases. This suggests a defect in chromosome segregation during oogenesis, rather than defective spermatogenesis. Prolonged retention of oocytes or sperm in the reproductive tract before fertilization does not seem to be a cause of nondisjunction leading to Down syndrome or of major birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/10\">",
"     10",
"    </a>",
"    ], but altered recombination appears to have a role [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In this model, age-related perturbations in the meiotic machinery cause homologues with susceptible crossover configurations to segregate incorrectly. Distal crossovers may be unable to lock homologues together, allowing them to move independently and possibly drift together to the same spindle pole; pericentromeric crossovers may lock homologues too tightly, so they are unable to separate from one another and thus migrate together to the same spindle pole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonallelic homologous recombination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other sporadic chromosomal defects occur through abnormalities in recombination, which refers to the natural process of breaking and rejoining DNA strands during meiosis to produce new combinations of genes and, thus, generate genetic variation.",
"   </p>",
"   <p>",
"    Nonallelic homologous recombination (NAHR) typically involves the exchange of unequal amounts of genetic material during pairing between homologous chromosomes. Thus, the gene copy number is altered or hybrid genes are formed with novel properties. Single-gene phenotypes (ie, a trait or series of traits that can be attributed to mutation in a single gene), are produced that may be transmitted in a Mendelian fashion. For the X and Y chromosomes, the frequency of new unequal recombinational events is approximately 1:30,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/13\">",
"     13",
"    </a>",
"    ]. Structural variation of chromosomes can increase the frequency of unequal recombination.",
"   </p>",
"   <p>",
"    Unequal recombination may delete or disrupt one or more genes; in the latter case, two or more Mendelian phenotypes can be produced. This condition is called a \"contiguous gene syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosome inversions are the result of abnormal recombinational events. There are two types of inversion (",
"    <a class=\"graphic graphic_figure graphicRef65339 \" href=\"UTD.htm?14/40/14978\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paracentric, involving both sides of the centromere.",
"     </li>",
"     <li>",
"      Pericentric, involving only one side [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paracentric chromosomes form inversion loops to pair with their normal chromosome partners. If crossing over occurs outside the inversion loop, then no abnormal products are formed. If the breakage and recombination occur within the loop, the products have both duplicated and deleted segments, a phenomenon that is referred to as \"recombination aneusomy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/17\">",
"     17",
"    </a>",
"    ]. The phenotype may be abnormal if the duplicated and deleted regions in the offspring are large in size. The sites of recombination may vary from one gamete to another, so that each offspring may appear to be a sporadic case with a novel phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Deletions and duplications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions are missing portions of a chromosome, while duplications involve an extra copy of a portion of the chromosome. Deletion carriers are effectively monosomic for the genes in the missing segment, whereas duplication carriers are trisomic for the duplicated genes. Deletions and duplications are generally described by their location (eg, duplication 4p) or by the two chromosomal break points defining the defective area (4p15.2,16.1). If the deletion is a common one, it may be defined by an eponym (5 p minus is known as Cri du Chat syndrome).",
"   </p>",
"   <p>",
"    Larger deletions and duplications can be identified cytogenetically because these banding patterns are unique to each chromosome. However, microdeletions and microduplications may be too small to be detected by traditional cytogenetic techniques and may require molecular techniques. Common",
"    <span class=\"nowrap\">",
"     microdeletions/duplications",
"    </span>",
"    can be identified by fluorescence in situ hybridization (FISH) using a probe for the deleted or duplicated genes or by array genomic hybridization using microarrays (DNA chips).",
"   </p>",
"   <p>",
"    Some deletions occur more frequently than would be expected by chance alone and cause several specific contiguous gene deletion syndromes. DiGeorge syndrome, as an example, usually results from a microdeletion of the long arm of chromosome 22 (22q11.2) and is associated with phenotypic abnormalities due to defects of the fourth branchial arch and adjacent structures (ie, a developmental field defect). Clinical manifestations include: thymic and parathyroid hypoplasia or aplasia, aortic arch malformations, short palpebral fissures, micrognathia with a short philtrum, and ear anomalies. Another common contiguous gene deletion syndrome is terminal deletion of the short arms of the 4th chromosome (4 p minus, or Wolf-Hirschhorn syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Translocations are rearrangements that occur as a result of breaks in each of two different chromosomes with subsequent joining of the non-contiguous ends. In a number of cases in which the breakpoints of the translocated chromosomes have been identified, the sites of recombination were shown to involve both homologous and non-homologous DNA sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These occur via NAHR or non-homologous end-joining. If the chromosomal constitution is such that there has been no net loss or gain of information, then the translocation is considered to be balanced.",
"   </p>",
"   <p>",
"    By comparison, if the net genetic information has changed, then the translocation is unbalanced (",
"    <a class=\"graphic graphic_figure graphicRef71519 \" href=\"UTD.htm?25/32/26113\">",
"     figure 4",
"    </a>",
"    ). Unbalanced translocations produce variant phenotypes by changing the gene copy number through deletion or duplication, and by interrupting genes and putting them under the control of new regulatory elements. This may be recognizable as a Mendelian condition, such as Duchenne muscular dystrophy or neurofibromatosis I [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, physical rearrangement of chromosomes, including translocations, may cause the chromosomes to be transmitted in a non-Mendelian, but predictable, pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the duplicated and deleted chromosomal regions may contribute to the phenotype, although one may be overriding. As an example, the deletion of one of the short arms of chromosome 17 may produce isolated lissencephaly (smooth brain) despite the fact that there may be a duplicated segment on another chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/22\">",
"     22",
"    </a>",
"    ]. This suggests that no genes are present in these duplicate regions or that dosage alterations of genes in these regions do not affect the phenotype in ways that have been recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SINGLE GENE DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patterns of inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants are at increased risk for having birth defects if their parents are carriers of genetic mutations. Three traditional patterns of single gene transmission are recognized in humans, although distinctions among them have become increasingly blurred as more sensitive biochemical markers of phenotype expression become available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"     \"Basic principles of genetic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Autosomal dominant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant traits are generally expressed in the heterozygous state (",
"    <a class=\"graphic graphic_figure graphicRef71414 \" href=\"UTD.htm?4/20/4417\">",
"     figure 5",
"    </a>",
"    ). The likelihood of transmitting a dominant trait from parent to child is usually 50 percent. Generally, these traits are expressed equally in male and female offspring. For some dominant traits, such as familial hypercholesterolemia and factor V Leiden, the phenotype may be more severe in the homozygous than the heterozygous state. For other traits, including blood groups and hemoglobin variants, expression of the allele from each of the parents can be demonstrated, a phenomenon that is referred to as co-dominance.",
"   </p>",
"   <p>",
"    The phenotype of an individual carrying a gene with an autosomal dominant mutation may vary based upon the penetrance and expressivity of the mutation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penetrance indicates whether or not the mutant gene is expressed as a specific phenotype. If a dominant mutation produces a characteristic abnormal phenotype expression in all affected individuals, it has complete penetrance, whereas a dominant mutation whose characteristic phenotype is not present in all affected individuals has incomplete penetrance.",
"     </li>",
"     <li>",
"      Expressivity is the extent to which an autosomal dominant mutation that is penetrant produces characteristic phenotypic features. If all individuals carrying the affected gene do not share very similar phenotypes, the mutation has variable expressivity. Such a gene can produce a range of phenotypic features, from mild to severe. Neurofibromatosis is an example of a disease with variable expressivity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Autosomal recessive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive traits are generally expressed in homozygotes, but not in heterozygotes (",
"    <a class=\"graphic graphic_figure graphicRef50436 \" href=\"UTD.htm?6/3/6194\">",
"     figure 6",
"    </a>",
"    ). The usual likelihood that carrier parents will have affected offspring is 25 percent. Proof of this pattern of inheritance requires demonstrating that both parents are heterozygotes. This can be readily accomplished if each of the parental alleles can be identified. As an example, electrophoretic analysis of affected individuals with sickle cell anemia will reveal primarily the S form of the hemoglobin beta chain, while carriers will demonstrate both S and A forms.",
"   </p>",
"   <p>",
"    Double heterozygotes carry two different mutated versions of a given gene, with pathological consequences. As an example, in hemoglobin SC disease an affected individual has inherited both an S and a C beta hemoglobin chain mutated gene from his or her parents. Currently, many heterozygote detection tests are performed by direct analysis of DNA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autosomal recessive conditions are found more commonly in ethnic groups who marry within the group or in consanguineous relationships, because recessive genes are relatively rare. Consanguineous marriages occur in most populations. It is a customary practice in the Middle East, in parts of South Asia and Southeast Asia, and among many tribes in sub-Saharan Africa people who have migrated from these parts of the world to other countries may still practice consanguineous marriages. On a global basis, it is estimated that at least 20 percent of people live in communities with a preference for consanguineous marriage and that &ge;8.5 percent of children have consanguineous parents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/23\">",
"     23",
"    </a>",
"    ]. The birth prevalence of congenital and genetic disorders among offspring of consanguineous couples is about double that compared to non-consanguineous couples (7.9 versus 4.3 percent in the Birmingham Birth Study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/24\">",
"     24",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     X-linked conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;These disorders are more commonly manifested in males than females. Males transmit their Y rather than their X chromosome to their sons, thus X linkage is characterized by the absence of male-to-male transmission (",
"    <a class=\"graphic graphic_figure graphicRef53159 \" href=\"UTD.htm?26/41/27281\">",
"     figure 7",
"    </a>",
"    ). By comparison, all of the daughters of affected males inherit the gene for the disorder. X-linked dominant conditions are those for which the presence of a single allele is sufficient to result in expression in females, whereas X-linked recessive conditions require two alleles for expression in females. Relatively few X-linked dominant conditions have been identified. These conditions (eg, hypophosphatemic rickets and adrenomyeloneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/25\">",
"     25",
"    </a>",
"    ]) are generally milder in females than they are in males. Some X-linked dominant conditions, such as incontinentia pigmenti and Rett syndrome, are rarely observed in males and are presumed to be lethal to the affected male embryo since it has only one X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catalog for clinical phenotypes is Mendelian Inheritance in Man, originally published by Victor McKusick in 1964, and now updated on a continuous basis by him and others in an online version (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim\">",
"     www.ncbi.nlm.nih.gov/omim",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/28\">",
"     28",
"    </a>",
"    ]. The catalog lists over 7000 conditions, which represent distinct phenotypes or allelic forms of a disorder.",
"   </p>",
"   <p>",
"    The frequency of single gene disorders in North America was tracked by the British Columbia Birth Defects Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/29\">",
"     29",
"    </a>",
"    ]. The overall frequency was estimated to be 1 percent, with 0.7 percent as dominant conditions, 0.25 percent as recessive conditions, and 0.04 percent as X-linked conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of disadaptive Mendelian phenotypes in humans has been examined using Mendelian Inheritance in Man as a guide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/31\">",
"     31",
"    </a>",
"    ]. Twenty-five percent of these phenotypes are apparent at birth, and over 90 percent by the end of puberty. Conditions with decreased reproductive fitness are generally manifested earlier in life.",
"   </p>",
"   <p>",
"    Disadaptive Mendelian phenotypes typically require that some cumulative damage occur before they become apparent. Over one-half of the phenotypes involve more than one anatomic or functional system. Lifespan is reduced in 57 percent of these disorders, more commonly in autosomal recessive and X-linked diseases; reproductive capacity is reduced in 69 percent; and the nervous system is affected in over 30 percent. The age of appearance tends to be more variable for autosomal dominant compared to autosomal recessive or X-linked conditions. However, studies of frequency, morbidity, and fitness of single-gene conditions were based upon known human disorders. Therefore, these figures may represent an underestimate because the Mendelian basis for fetal and adult-onset disorders may not have been recognized when the studies were performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NON-MENDELIAN PATTERNS OF INHERITANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Unstable DNA and fragile X syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain genes have been found to be inherently unstable triplet repeat regions, with the number of triplet repeats (usually cytosine-guanine-guanine (CGG)n) varying during both meiosis and mitosis. If the number of triplet repeats reaches a critical level, the affected gene can become methylated and, thus inactivated. This can result in phenotypic abnormalities.",
"   </p>",
"   <p>",
"    Some triplet regions expand only during female meiosis, while others can expand when transmitted by either parent. As an example, fragile X syndrome is due to the fragile X mutation, which is a region of unstable CGG triplet repeats on the X chromosome at the position, Xq27. This region is inactivated by methylation when it reaches a critical size: individuals carrying 2 to 49 repeats are phenotypically normal; those carrying 50 to 199 repeats are also asymptomatic, although they are said to have a premutation which can expand if it is passed on to an offspring; and those with more than 200 repeats have the full mutation and, if methylation occurs, are usually affected. Phenotypic variability is caused by lyonization in affected females and mosaicism due to selective mitotic expansion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    variable degrees of methylation in both males and females. Therefore, it is exceedingly difficult to precisely predict an offspring's degree of neurologic abnormality.",
"   </p>",
"   <p>",
"    Fragile X syndrome is the most common form of familial intellectual disability in males. Affected individuals have mild to severe intellectual disability, attention deficit-hyperactivity disorder, speech and language problems, narrow face with large jaw, long prominent ears, macroorchidism (in postpubertal males), and, occasionally, seizures. The incidence of the full fragile X syndrome is generally quoted as",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    males and",
"    <span class=\"nowrap\">",
"     1/2000",
"    </span>",
"    females.",
"   </p>",
"   <p>",
"    Fragile X syndrome was originally diagnosed by culturing cells in a folate deficient medium and then assessing the cultures for X-chromosome breakage by cytogenetic analysis of the long arm of the X chromosome (Xq27-28). This technique proved unreliable for both diagnosis and carrier testing. The fragile X abnormality is now directly determined by analysis of the number of CGG repeats and their methylation status using restriction endonuclease digestion and Southern blot analysis.",
"   </p>",
"   <p>",
"    Other autosomal dominant neurologic disorders caused by triplet repeat expansion include myotonic dystrophy, Huntington chorea, Friedreich ataxia, X-linked spinal, bulbar muscular atrophy (Kennedy's disease), and spinocerebellar ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Imprinting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imprinting refers to the differential expression of genetic material depending upon whether it was inherited from the male or female parent. Thus, the same genetic information transmitted from a mother or a father can result in a different phenotype because the alleles are reversibly modified in the parental gametes such that in the offspring the two alleles are expressed in functionally different ways. Imprinted genes are inactivated by methylation of their promoter region; this chemical modification of the gene allele can be used to identify maternal or paternal origin of chromosome. The extent of the imprinting is determined by the gender of the transmitting parent. Gene function is dependent upon the active gene inherited from the other parent.",
"   </p>",
"   <p>",
"    Imprinted genes can cause genetic disease if the nonimprinted, active gene is mutated or deleted. As an example, two distinct genetic diseases with very different phenotypes result from the same chromosomal deletion at 15q11-13 depending upon the parental source of both the imprinted and deleted gene. If the paternally-derived chromosome 15 is deleted, the result is Prader-Willi syndrome, which is characterized by obesity; hyperphagia; short stature; small hands, feet, and external genitalia; and mild intellectual disability. In contrast, if the maternally-derived chromosome 15 is deleted, the affected individual will have Angelman syndrome, which is characterized by normal stature and weight, severe intellectual disability, absent speech, seizures, ataxia and jerky arm movements, and paroxysms of inappropriate laughter. A deletion is not absolutely required to produce the phenotype. If an individual has two normal intact copies of chromosome 15, but both came from the father (ie, uniparental disomy), the phenotype is Angelman syndrome. Conversely, uniparental disomy (",
"    <a class=\"graphic graphic_figure graphicRef72197 \" href=\"UTD.htm?12/1/12307\">",
"     figure 8",
"    </a>",
"    ) resulting in two maternal copies of chromosome 15 produces Prader-Willi syndrome. The risk of the imprinting disorders, Angelman syndrome and Beckwith-Wiedeman syndrome, appears to be increased among children conceived by intracytoplasmic sperm injection (ICSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/32\">",
"     32",
"    </a>",
"    ]. It is unclear whether this association is related to ICSI, in vitro fertilization, or subfertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mitochondrial inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondria have a small amount of their own DNA (mtDNA), which is a relatively small portion of total body DNA. This DNA is also subject to deletion or point mutation and several diseases associated with mutations in mtDNA have been found. The inheritance patterns of these disorders are unique since an individual inherits virtually all of his mtDNA from his mother, not from his father. This occurs because the relatively large ovum has many copies of mitochondrial DNA while the sperm has very few, and these are lost during fertilization. The inheritance pattern of mitochondrial DNA disorders is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children of affected males will not inherit the disease.",
"     </li>",
"     <li>",
"      Approximately 4 percent (95% CI 0.86-11.54) of children of females affected with a mitochondrial deletion disorder will inherit it [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/33\">",
"       33",
"      </a>",
"      ]. Children of women with a mitochondrial point mutation will inherit the mutation, but the risk of developing the disease, such as Leber hereditary optic neuropathy, is about 50 percent for males and about 10 percent for females [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/34\">",
"       34",
"      </a>",
"      ]. The reason for this gender discordance is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mitochondrial deletion disorders include Kearns&ndash;Sayre syndrome, chronic progressive external ophthalmoplegia, and Pearson bone-marrow pancreas syndrome. Mitochondrial point mutation disorders include Leber hereditary optic neuropathy, myoclonic epilepsy with ragged red fibers (MERRF), and Leigh syndrome (ataxia, hypotonia, spasticity, and optic abnormalities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Germline or gonadal mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitotic errors occurring in embryonic cells destined to become the gonad can cause gonadal mosaicism. This entity may explain the occurrence of autosomal dominant mutations causing disease in the absence of a family history. Some examples are achondroplasia or osteogenesis imperfecta or X-linked diseases, such as Duchenne muscular dystrophy. Gonadal mosaicism may account for 6 percent of cases of new autosomal dominant or X-linked recessive mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Multifactorial and polygenic traits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most inherited traits (eg, height and intelligence) are multifactorial or polygenic: they result from the combined effects of multiple genes interacting with environmental factors. Birth defects caused by this mechanism recur at a far lower rate than those inherited by a Mendelian inheritance pattern. The recurrence risk for first-degree relatives is generally about 2 or 3 percent (eg, neural tube defects). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some",
"    <span class=\"nowrap\">",
"     multifactorial/polygenic",
"    </span>",
"    disorders have a predilection for one gender. When a family includes an affected member who is of the less frequently affected gender, it indicates that a greater number of abnormal genes or environmental influences are present and, thus, the recurrence risk is higher. As an example, pyloric stenosis is more common in males, therefore when an infant girl is affected, the recurrence risk for her siblings or for her future children is higher than expected. Her male siblings or offspring will have the highest risk of the disease because they are the most susceptible sex; they will also inherit more than the usual number of predisposing genes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"     \"Infantile hypertrophic pyloric stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recurrence risk of",
"    <span class=\"nowrap\">",
"     multifactorial/polygenic",
"    </span>",
"    disorders is also higher if the defect is more severe, since severity is another indication of a greater burden of abnormal genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental influences. As an example, the recurrence risk after the birth of an infant with bilateral cleft lip and palate is twice as high as that after birth of a child with unilateral cleft lip without cleft palate (8 versus 4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TERATOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A teratogen is an agent that can cause abnormalities in growth, form, or function of a developing fetus. It acts by producing cell death, altering normal growth of tissues, or interfering with normal cellular differentiation or other morphologic processes. The consequences of these actions can be fetal loss, fetal growth restriction, birth defects, or impaired neurologic performance. The following criteria by Shepard have been derived from Koch's postulates and can be used to establish the teratogenicity of an agent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;1 - Exposure to the agent at critical time(s) in prenatal development",
"   </p>",
"   <p>",
"    &nbsp;2 - Consistent dysmorphic findings reported by high quality epidemiologic studies",
"   </p>",
"   <p>",
"    &nbsp;3 - Careful delineation of the clinical cases, ideally with a specific defect or syndrome",
"   </p>",
"   <p>",
"    &nbsp;4 - The presence of a rare environmental exposure associated with a rare defect",
"   </p>",
"   <p>",
"    &nbsp;5 - Teratogenicity observed in experimental animal studies",
"   </p>",
"   <p>",
"    &nbsp;6 - The observed association between the agent and the defect is biologically plausible",
"   </p>",
"   <p>",
"    &nbsp;7 - The agent acts in an unaltered state",
"   </p>",
"   <p>",
"    Items 1 to 3 or 1, 3, and 4 are essential; 5 to 7 are helpful, but not essential.",
"   </p>",
"   <p>",
"    Approximately 10 percent of birth defects are caused by exposure to teratogens in the environment. These include maternal illnesses, infectious agents, physical agents, and drugs and chemical agents. Timing is a critical factor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The all-or-none rule is thought to apply during the first two weeks after conception. If only a few cells are damaged, then their roles may be compensated by other totipotent cells. If too many cells are damaged, then the early embryo will not implant or will be spontaneously aborted.",
"     </li>",
"     <li>",
"      The embryo is most vulnerable to teratogenic insults since organogenesis is occurring during the embryonic period of development (",
"      <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"       figure 9",
"      </a>",
"      ). The embryonic period in humans can be defined as from fertilization until the end of the 10th week of gestation (8th week postconception).",
"     </li>",
"     <li>",
"      During the fetal period (",
"      <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"       figure 9",
"      </a>",
"      ), teratogens can cause cell death, retardation of cell growth, or inhibition of normal differentiation. This may result in fetal growth restriction or disorders of the central nervous system that may not be apparent at birth. The eyes, genitalia, central nervous system, and hematopoietic systems continue to develop during the fetal period and remain susceptible to teratogenic insults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Response to the teratogenic agent is highly individual, influenced not only by timing and dose, but also by the genetic make-up of the mother and the fetus (host susceptibility).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Maternal illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several maternal illnesses are associated with birth defects. In each of these conditions, a metabolite or antibody diffuses across the placenta and is toxic to the fetus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregestational diabetes mellitus is associated with a two to three-fold increase in risk of congenital anomalies, including congenital heart disease and spina bifida, and, less commonly, caudal regression and focal femoral hypoplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"       \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"       \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"      </a>",
"      .) Infants of diabetic mothers are at increased risk for abnormal growth and for hypoglycemia in the newborn period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"       \"Infant of a diabetic mother\"",
"      </a>",
"      .) All of these risks can be diminished by strict control of the maternal glucose concentration from the time of conception to the time of delivery (",
"      <a class=\"graphic graphic_figure graphicRef67498 \" href=\"UTD.htm?43/27/44477\">",
"       figure 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phenylketonuria is associated with microcephaly, intellectual disability, and congenital heart disease. These abnormalities are thought to result from diffusion of toxic amounts of phenylalanine and its metabolites across the placenta. The risk can be minimized by maternal dietary control of the disease starting from conception and continuing throughout the pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Androgen producing tumors of the adrenal glands or ovaries can produce virilization of female fetuses.",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus is associated with fetal, but not maternal, heart block. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal obesity has been associated with an increased risk of certain types of birth defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H30#H30\">",
"     \"The impact of obesity on fertility and pregnancy\", section on 'Congenital anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to infectious agents can result in a variety of problems in the fetus and neonate, including malformations, congenital infection, short and long-term disability, and death. In some instances, the infection may be asymptomatic in the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/39\">",
"     39",
"    </a>",
"    ]. The pathogenesis of the fetal defects is usually direct invasion of fetal tissues leading to damage from inflammation and cell death.",
"   </p>",
"   <p>",
"    Agents known to be toxic to the fetus or embryo are toxoplasmosis, rubella, cytomegalovirus, herpes, and syphilis (the so-called TORCH infections), as well as varicella and parvovirus B19 and lymphocytic choriomeningitis virus (LCMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. Prior immunization is an effective means for preventing rubella and varicella infections during pregnancy. Maternal treatment of syphilis during pregnancy can improve the outcome for both mother and fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=see_link\">",
"     \"Parvovirus B19 infection during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H9#H9\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Other viruses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonspecific sonographic signs suggestive of fetal infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microcephaly",
"     </li>",
"     <li>",
"      Cerebral or hepatic calcifications",
"     </li>",
"     <li>",
"      Intrauterine growth restriction",
"     </li>",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Cardiac malformations, limb hypoplasia, hydrocephalus",
"     </li>",
"     <li>",
"      Hydrops",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonates with birth defects associated with disorders of movement and muscle tone, chorioretinitis or cataracts, hearing impairment, hepatosplenomegaly, skin rash, thrombocytopenia, jaundice, or low birth weight are suspects for congenital infection.",
"   </p>",
"   <p>",
"    Fever associated with infection also can be teratogenic. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Fever/hyperthermia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal drug ingestion, both medical and recreational, can cause adverse fetal and neonatal outcomes. Nonpregnant women are sometimes prescribed medications that are contraindicated in pregnancy because of evidence that the risk of birth defects outweighs any potential benefits of the medication (ie, US Food and Drug Administration category X). These women should be counseled about the adverse effects of these medications and the importance of consistent use of effective contraception. Despite these measures, one study found that 40 percent of women who were prescribed category X medications and oral contraception had refill patterns suggesting suboptimal adherence to the oral contraceptive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/46\">",
"     46",
"    </a>",
"    ]. This pattern of contraceptive use highlights the difficulty in preventing",
"    <span class=\"nowrap\">",
"     embryo/fetal",
"    </span>",
"    exposure to these medications and the desirability of using equivalent but safer medications or other forms of therapy, if available, in women of childbearing potential.",
"   </p>",
"   <p>",
"    Some common teratogenic medications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensin converting enzyme inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticonvulsant agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link\">",
"       \"Risks associated with epilepsy and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antineoplastic agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=see_link\">",
"       \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=see_link\">",
"       \"Management of classical Hodgkin lymphoma during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      , retinoic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/47-58\">",
"       47-58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A partial list of additional known teratogens is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef73369 \" href=\"UTD.htm?4/58/5024\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinoic acid is highly teratogenic in the first trimester of pregnancy, leading to spontaneous abortions and fetal malformations, including microcephaly and cardiac anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/59\">",
"       59",
"      </a>",
"      ]. At doses of only several times the RDA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/60\">",
"       60",
"      </a>",
"      ], many animal models as well as human studies have shown high incidence of birth defects in mothers who ingested therapeutic doses of retinoic acid for dermatological uses [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/59\">",
"       59",
"      </a>",
"      ]. A safe upper limit for vitamin A intake has been recognized at about 800 to 10,000",
"      <span class=\"nowrap\">",
"       IU/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      should not be used by women who want to become pregnant as conception is",
"      <strong>",
"       contraindicated for at least three years after discontinuation",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      Androgenic agents, such as testosterone or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      , do not cause malformation, but can virilize a female fetus. Cocaine induced vasoconstriction of uterine vessels is one mechanism for fetal damage from this substance [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/62\">",
"       62",
"      </a>",
"      ]. Infants whose mothers consume alcohol during pregnancy can have fetal alcohol effects (FAE), alcohol-related birth defects (ARBD), fetal alcohol syndrome, or they may be normal [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"       \"Alcohol intake and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) increase the risk of neural-tube defects and possibly cardiovascular defects, oral clefts, and urinary tract defects [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/64\">",
"       64",
"      </a>",
"      ] and placenta-mediated adverse pregnancy outcomes, including preeclampsia, placental abruption, fetal growth restriction, and fetal death [",
"      <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific information on the fetal and neonatal risks of maternal drug ingestion during pregnancy and lactation are available from several resources , including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.perinatology.com/exposures/druglist.htm\">",
"       www.perinatology.com/exposures/druglist.htm",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.reprotox.org/\">",
"       www.reprotox.org/",
"      </a>",
"      (requires subscription)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.otispregnancy.org/\">",
"       www.OTISpregnancy.org",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://depts.washington.edu/terisweb/teris/\">",
"       file://depts.washington.edu/terisweb/teris/",
"      </a>",
"      (requires subscription)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.motherisk.org/women/drugs.jsp\">",
"       www.motherisk.org/women/drugs.jsp",
"      </a>",
"     </li>",
"     <li>",
"      UpToDate drug information database",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Physical and environmental agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of physical agents and environmental chemicals have been implicated in the pathogenesis of birth defects. It is impossible to generate a complete list and discussion of environmental teratogens here, but numerous resources are available (eg,",
"    <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/\">",
"     file://toxnet.nlm.nih.gov/",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.otispregnancy.org/\">",
"     www.OTISpregnancy.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Lead",
"    </span>",
"    &nbsp;&mdash;&nbsp;High plasma lead levels are associated with adverse neurobehavioral effects in infants and children; intrauterine exposure may have similar consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/66\">",
"     66",
"    </a>",
"    ]. Studies of potential associations between parental lead exposure and congenital malformations in offspring have not demonstrated a consistent increase in risk or pattern of defects, but often lack biological indices of exposure at developmentally significant times [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link&amp;anchor=H13#H13\">",
"     \"Occupational and environmental risks to reproduction in females\", section on 'Lead'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of ionizing radiation on the",
"    <span class=\"nowrap\">",
"     embryo/fetus",
"    </span>",
"    are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Fever/hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevation of maternal core temperature from a febrile illness or other source (eg, hot tub) in the first trimester of pregnancy may be associated with an increased risk for neural tube defects or miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. The consequences of hyperthermia depend on the extent of temperature elevation, its duration, and the stage of development when it occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/70\">",
"     70",
"    </a>",
"    ]. In one study of a cohort of 23,491 women who underwent serum alpha-fetoprotein screening or an amniocentesis, exposure to heat in the form of hot tub, sauna, or fever in the first trimester of pregnancy was associated with an approximately two-fold increase in risk for NTDs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/68\">",
"     68",
"    </a>",
"    ]. Additionally, a meta-analysis of 15 studies comprising 1719 cases of neural tube defects and 37,898 non-cases found that the overall odds ratio for neural tube defects associated with maternal hyperthermia was 1.92 (95% CI 1.61-2.29) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Birth Defects Prevention Study observed that, among women with infection-related fever, single agent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    was not associated with an increase in the overall risk of birth defects, and was associated with a statistically significant reduction in neural tube defects, as well as cleft",
"    <span class=\"nowrap\">",
"     lip/palate",
"    </span>",
"    and gastroschisis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/72\">",
"     72",
"    </a>",
"    ]. These data support the safety of acetaminophen for relief of fever and pain; however, the reduction in birth defects should be confirmed in other studies before acetaminophen is recommended to febrile women for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Fish consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methylmercury exposure, primarily through ingestion of contaminated fish, can cause severe central nervous system damage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/73\">",
"     73",
"    </a>",
"    ], as well as milder intellectual, motor, and psychosocial impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/13/7386/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Some limitations on fish intake during pregnancy are recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H20#H20\">",
"     \"Nutrition in pregnancy\", section on 'Dietary restrictions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33273?source=see_link\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DEFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deformations are abnormalities that are mechanically produced by alterations of the normal fetal environment. These alterations may be physical constraints or related to vascular accidents. Amniotic bands, as an example, can constrict a developing body part and compromise its blood supply leading to amputation involving the limb, cranium, or body wall. Oligohydramnios may compress the fetus, sometimes causing a flattened facial appearance (ie, Potter's facies). In addition, alterations of normal amniotic fluid pressure and egress of lung fluid may result in pulmonary hypoplasia. The position of the fetus in the uterus (eg, breech) can influence its development by altering head shape or neck positioning in the absence of external influences. Intrauterine leiomyoma or other uterine structural anomalies rarely may cause fetal deformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36902?source=see_link\">",
"     \"Amniotic band sequence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal abnormalities affect approximately 1 in 200 newborn infants. These defects may be either sporadic or heritable and are due to different etiologies, such as nondisjunction, recombination, inversion, deletion, duplication, and translocation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Structural chromosomal abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of single gene disorders is estimated to be 1 percent, with 0.7 percent as dominant conditions, 0.25 percent as recessive conditions and 0.04 percent as X-linked conditions. Twenty-five percent of these phenotypes are apparent at birth, and over 90 percent are apparent by the end of puberty. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Single gene disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonmendelian patterns of inheritance may involve unstable triplet repeat regions, imprinting, mitochondrial inheritance, germline mosaicism, and multifactorial inheritance. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Non-Mendelian patterns of inheritance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A teratogen is an agent that can cause abnormalities in form or function of a developing fetus. Maternal exposure to drugs, medical disorders, infection, and environmental agents can be teratogenic. A partial list of additional known teratogens is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef73369 \" href=\"UTD.htm?4/58/5024\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Teratogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deformations are abnormalities that are mechanically produced by alterations of the normal fetal environment, such as amniotic bands or oligohydramnios. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Deformations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/1\">",
"      Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Teratology 1999; 59:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/2\">",
"      Jacobs PA, Melville M, Ratcliffe S, et al. A cytogenetic survey of 11,680 newborn infants. Ann Hum Genet 1974; 37:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/3\">",
"      Hamerton JL, Canning N, Ray M, Smith S. A cytogenetic survey of 14,069 newborn infants. I. Incidence of chromosome abnormalities. Clin Genet 1975; 8:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/4\">",
"      Bou&eacute; A, Bou&eacute; J. Chromosome abnormalities and abortion. Basic Life Sci 1974; 4:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/5\">",
"      Burgoyne PS, Holland K, Stephens R. Incidence of numerical chromosome anomalies in human pregnancy estimation from induced and spontaneous abortion data. Hum Reprod 1991; 6:555.",
"     </a>",
"    </li>",
"    <li>",
"     Sutherland, GRJM. Chromosome Abnormalities and Genetic Counseling, Oxford University Press, New York, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/7\">",
"      Thomas NS, Ennis S, Sharp AJ, et al. Maternal sex chromosome non-disjunction: evidence for X chromosome-specific risk factors. Hum Mol Genet 2001; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/8\">",
"      Risch N, Stein Z, Kline J, Warburton D. The relationship between maternal age and chromosome size in autosomal trisomy. Am J Hum Genet 1986; 39:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/9\">",
"      Hassold T, Warburton D, Kline J, Stein Z. The relationship of maternal age and trisomy among trisomic spontaneous abortions. Am J Hum Genet 1984; 36:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/10\">",
"      Simpson JL, Gray R, Perez A, et al. Fertilisation involving ageing gametes, major birth defects, and Down's syndrome. Lancet 2002; 359:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/11\">",
"      Lamb, NE, Hassold, TJ. Nondisjunction &mdash; A view from ringside. N Engl J Med 2004; 19:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/12\">",
"      Lamb NE, Sherman SL, Hassold TJ. Effect of meiotic recombination on the production of aneuploid gametes in humans. Cytogenet Genome Res 2005; 111:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/13\">",
"      de la Chapelle A. Analytic review: nature and origin of males with XX sex chromosomes. Am J Hum Genet 1972; 24:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/14\">",
"      Schmickel RD. Contiguous gene syndromes: a component of recognizable syndromes. J Pediatr 1986; 109:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/15\">",
"      Madan K. Paracentric inversions: a review. Hum Genet 1995; 96:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/16\">",
"      Pericentric inversions in man. A French collaborative study. Groupe de Cytogeneticiens Francais. Annales Genet 1986; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/17\">",
"      Schroeder HW Jr, Forbes S, Mack L, et al. Recombination aneusomy of chromosome 5 associated with multiple severe congenital malformations. Clin Genet 1986; 30:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/18\">",
"      van Bakel I, Holt S, Craig I, Boyd Y. Sequence analysis of the breakpoint regions of an X;5 translocation in a female with Duchenne muscular dystrophy. Am J Hum Genet 1995; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/19\">",
"      Petit C, de la Chapelle A, Levilliers J, et al. An abnormal terminal X-Y interchange accounts for most but not all cases of human XX maleness. Cell 1987; 49:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/20\">",
"      Monaco AP, Kunkel LM. Cloning of the Duchenne/Becker muscular dystrophy locus. Adv Hum Genet 1988; 17:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/21\">",
"      Ledbetter DH, Rich DC, O'Connell P, et al. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet 1989; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/22\">",
"      Dobyns WB, Truwit CL. Lissencephaly and other malformations of cortical development: 1995 update. Neuropediatrics 1995; 26:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/23\">",
"      Modell B, Darr A. Science and society: genetic counselling and customary consanguineous marriage. Nat Rev Genet 2002; 3:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/24\">",
"      Bundey S, Alam H. A five-year prospective study of the health of children in different ethnic groups, with particular reference to the effect of inbreeding. Eur J Hum Genet 1993; 1:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/25\">",
"      Moser HW, Moser AE, Singh I, O'Neill BP. Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol 1984; 16:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/26\">",
"      LENZ W. [On the genetics of incontinentia pigmenti]. Ann Paediatr 1961; 196:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/27\">",
"      Comings DE. The genetics of Rett syndrome: the consequences of a disorder where every case is a new mutation. Am J Med Genet Suppl 1986; 1:383.",
"     </a>",
"    </li>",
"    <li>",
"     McKusick, VA. \"Mendelian Inheritance in Man\", Johns Hopkins University Press, Baltimore, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/29\">",
"      Baird PA, Anderson TW, Newcombe HB, Lowry RB. Genetic disorders in children and young adults: a population study. Am J Hum Genet 1988; 42:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/30\">",
"      Baird PA. Measuring birth defects and handicapping disorders in the population: the British Columbia Health Surveillance Registry. CMAJ 1987; 136:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/31\">",
"      Costa T, Scriver CR, Childs B. The effect of Mendelian disease on human health: a measurement. Am J Med Genet 1985; 21:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/32\">",
"      Allen C, Reardon W. Assisted reproduction technology and defects of genomic imprinting. BJOG 2005; 112:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/33\">",
"      Chinnery PF, DiMauro S, Shanske S, et al. Risk of developing a mitochondrial DNA deletion disorder. Lancet 2004; 364:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/34\">",
"      Man PY, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet 2002; 39:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/35\">",
"      Shepard TH. \"Proof\" of human teratogenicity. Teratology 1994; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/36\">",
"      Garner P. Type I diabetes mellitus and pregnancy. Lancet 1995; 346:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/37\">",
"      Waisbren SE, Hanley W, Levy HL, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA 2000; 283:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/38\">",
"      Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. Teratology 1996; 53:176.",
"     </a>",
"    </li>",
"    <li>",
"     Klein, JO, Baker, CJ, Remington, JS, Wilson, CB. Current concepts of infections of the fetus and newborn infant. In: Infectious Diseases of the Fetus and Newborn Infant, 6th ed, Remington, JS, Klein, JO, Wilson, CB, Baker, CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/40\">",
"      Webster WS. Teratogen update: congenital rubella. Teratology 1998; 58:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/41\">",
"      Lynfield R, Eaton RB. Teratogen update: congenital toxoplasmosis. Teratology 1995; 52:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/42\">",
"      Demmler GJ. Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis 1996; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/43\">",
"      Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998; 105:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/44\">",
"      Jordan EK, Sever JL. Fetal damage caused by parvoviral infections. Reprod Toxicol 1994; 8:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/45\">",
"      Bonthius DJ, Perlman S. Congenital viral infections of the brain: lessons learned from lymphocytic choriomeningitis virus in the neonatal rat. PLoS Pathog 2007; 3:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/46\">",
"      Steinkellner A, Chen W, Denison SE. Adherence to oral contraception in women on Category X medications. Am J Med 2010; 123:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/47\">",
"      Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994; 50:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/48\">",
"      Hanson JW. Teratogen update: fetal hydantoin effects. Teratology 1986; 33:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/49\">",
"      Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. Teratology 1987; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/50\">",
"      Cragan JD. Teratogen update: methylene blue. Teratology 1999; 60:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/51\">",
"      Miller MT, Str&ouml;mland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 1999; 60:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/52\">",
"      Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. Teratology 1986; 33:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/53\">",
"      Rosa FW. Teratogen update: penicillamine. Teratology 1986; 33:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/54\">",
"      Warkany J. Teratogen update: lithium. Teratology 1988; 38:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/55\">",
"      Gonzalez CH, Marques-Dias MJ, Kim CA, et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998; 351:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/56\">",
"      Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/57\">",
"      Eller DP, Patterson CA, Webb GW. Maternal and fetal implications of anticonvulsive therapy during pregnancy. Obstet Gynecol Clin North Am 1997; 24:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/58\">",
"      Mulvihill JJ, McKeen EA, Rosner F, Zarrabi MH. Pregnancy outcome in cancer patients. Experience in a large cooperative group. Cancer 1987; 60:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/59\">",
"      Soprano DR, Soprano KJ. Retinoids as teratogens. Annu Rev Nutr 1995; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/60\">",
"      Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/61\">",
"      Biesalski HK, Hemmes C, El Hanafy M, et al. Long-term administration of high dose vitamin A to rats does not cause fetal malformations: macroscopic, skeletal and physicochemical findings. J Nutr 1996; 126:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/62\">",
"      Landry SH, Whitney JA. The impact of prenatal cocaine exposure: studies of the developing infant. Semin Perinatol 1996; 20:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/63\">",
"      Gladstone J, Nulman I, Koren G. Reproductive risks of binge drinking during pregnancy. Reprod Toxicol 1996; 10:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/64\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/65\">",
"      Wen SW, Zhou J, Yang Q, et al. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. CMAJ 2008; 179:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/66\">",
"      Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/67\">",
"      Rischitelli G, Nygren P, Bougatsos C, et al. Screening for elevated lead levels in childhood and pregnancy: an updated summary of evidence for the US Preventive Services Task Force. Pediatrics 2006; 118:e1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/68\">",
"      Milunsky A, Ulcickas M, Rothman KJ, et al. Maternal heat exposure and neural tube defects. JAMA 1992; 268:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/69\">",
"      Li DK, Janevic T, Odouli R, Liu L. Hot tub use during pregnancy and the risk of miscarriage. Am J Epidemiol 2003; 158:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/70\">",
"      Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol 2006; 76:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/71\">",
"      Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/72\">",
"      Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/73\">",
"      Harada M. Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology 1978; 18:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/74\">",
"      Crump KS, Kjellstr&ouml;m T, Shipp AM, et al. Influence of prenatal mercury exposure upon scholastic and psychological test performance: benchmark analysis of a New Zealand cohort. Risk Anal 1998; 18:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/13/7386/abstract/75\">",
"      Grandjean P, Weihe P, White RF, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol 1997; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     Kjellstrom, T, Kennedy, P, Wallis, S, et al. Physical and mental development of children with prenatal exposure to mercury from fish. Stage 1 and stage 2 results at ages 4 and six. National Swedish Envirnomental Board Reports #3080 (1980) and 3642 (1986).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6829 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7386=[""].join("\n");
var outline_f7_13_7386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMMON FEATURES OF CHROMOSOMAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STRUCTURAL CHROMOSOMAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nondisjunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonallelic homologous recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inversions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Deletions and duplications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Translocations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SINGLE GENE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patterns of inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Autosomal dominant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Autosomal recessive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - X-linked conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NON-MENDELIAN PATTERNS OF INHERITANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Unstable DNA and fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Imprinting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mitochondrial inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Germline or gonadal mosaicism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Multifactorial and polygenic traits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TERATOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Maternal illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Physical and environmental agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Lead",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Fever/hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Fish consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DEFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6829|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/11/27825\" title=\"figure 1\">",
"      Diagram of nondisjunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/16/34051\" title=\"figure 2\">",
"      Non-disjunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/40/14978\" title=\"figure 3\">",
"      Inversions and recombinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/32/26113\" title=\"figure 4\">",
"      Chromosomal translocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4417\" title=\"figure 5\">",
"      Autosomal dominant inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/3/6194\" title=\"figure 6\">",
"      Autosomal recessive inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/41/27281\" title=\"figure 7\">",
"      X linked inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/1/12307\" title=\"figure 8\">",
"      Uniparental disomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 9\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/27/44477\" title=\"figure 10\">",
"      HbA1c and fetal malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6829|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/15/36092\" title=\"table 1\">",
"      Frequency common birth defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17357\" title=\"table 2\">",
"      Maternal age-related Down syndrome risk at 3 gestational ages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/58/5024\" title=\"table 3\">",
"      Selected agents with potential adverse fetal effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36902?source=related_link\">",
"      Amniotic band sequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=related_link\">",
"      Basic principles of genetic counseling for the obstetrical provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=related_link\">",
"      Occupational and environmental risks to reproduction in females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=related_link\">",
"      Parvovirus B19 infection during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33273?source=related_link\">",
"      Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_13_7387="Tests of autonomic function";
var content_f7_13_7387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly performed tests of autonomic function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Principle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerves assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweat test",
"       </td>",
"       <td>",
"        Heat stimulates thermoregulatory center",
"       </td>",
"       <td>",
"        Central sympathetic adrenergic and peripheral sympathetic cholinergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BP lying, standing",
"       </td>",
"       <td>",
"        Postural BP control by adrenergic nerves",
"       </td>",
"       <td>",
"        Sympathetic adrenergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RR interval with deep breathing",
"       </td>",
"       <td>",
"        Vagal reflux bradycardia",
"       </td>",
"       <td>",
"        Cardiac vagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma pancreatic polypeptide response to modified sham feeding",
"       </td>",
"       <td>",
"        Sham feeding stimulates vagal center and efferents",
"       </td>",
"       <td>",
"        Efferent vagus to abdomen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7387=[""].join("\n");
var outline_f7_13_7387=null;
var title_f7_13_7388="Artery and nerve injuries associated with specific fractures";
var content_f7_13_7388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Artery and nerve injuries associated with specific fractures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fracture",
"       </td>",
"       <td class=\"subtitle1\">",
"        Artery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Upper extremity",
"        </strong>",
"       </td>",
"       <td>",
"        Proximal humerus",
"       </td>",
"       <td>",
"        <p>",
"         Axillary",
"        </p>",
"        <p>",
"         Brachial",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Axillary",
"        </p>",
"        <p>",
"         Suprascapular",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humerus shaft",
"       </td>",
"       <td>",
"        Brachial",
"       </td>",
"       <td>",
"        <p>",
"         Radial",
"        </p>",
"        <p>",
"         Median",
"        </p>",
"        <p>",
"         Ulnar",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supracondylar (humerus)",
"       </td>",
"       <td>",
"        Brachial",
"       </td>",
"       <td>",
"        <p>",
"         Median",
"        </p>",
"        <p>",
"         Radial",
"        </p>",
"        <p>",
"         Ulnar",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radius/ulna",
"       </td>",
"       <td>",
"        <p>",
"         Brachial",
"        </p>",
"        <p>",
"         Axillary",
"        </p>",
"        <p>",
"         Ulnar",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Median",
"        </p>",
"        <p>",
"         Ulnar",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Lower extremity",
"        </strong>",
"       </td>",
"       <td>",
"        Femur",
"       </td>",
"       <td>",
"        Femoral",
"       </td>",
"       <td>",
"        Femoral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tibia",
"       </td>",
"       <td>",
"        <p>",
"         Popliteal",
"        </p>",
"        <p>",
"         Anterior tibial",
"        </p>",
"        <p>",
"         Posterior tibial",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Tibial",
"        </p>",
"        <p>",
"         Superficial peroneal",
"        </p>",
"        <p>",
"         Deep peroneal",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schlickewei W, Kuner EH, Mullaji AB, et al. Upper and lower limb fractures with concomitant arterial injury. J Bone Joint Surg Br 1992; 74:181.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7388=[""].join("\n");
var outline_f7_13_7388=null;
var title_f7_13_7389="Rhabdomyosarcoma TNM staging";
var content_f7_13_7389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for rhabdomyosarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sites",
"      </td>",
"      <td class=\"subtitle1\">",
"       Tumor stage invasiveness",
"      </td>",
"      <td class=\"subtitle1\">",
"       T stage size",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       M",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       <p>",
"        Orbit",
"       </p>",
"       <p>",
"        Head and neck*",
"       </p>",
"       <p>",
"        Genitourinary&bull;",
"       </p>",
"       <p>",
"        Biliary tract",
"       </p>",
"      </td>",
"      <td>",
"       T",
"       <sub>",
"        1",
"       </sub>",
"       or T",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       a or b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M",
"       <sub>",
"        0",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       <p>",
"        Bladder/prostate",
"       </p>",
"       <p>",
"        Extremity",
"       </p>",
"       <p>",
"        Cranial parameningeal",
"       </p>",
"       <p>",
"        Other&Delta;",
"       </p>",
"      </td>",
"      <td>",
"       T",
"       <sub>",
"        1",
"       </sub>",
"       or T",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       a",
"      </td>",
"      <td>",
"       N",
"       <sub>",
"        0",
"       </sub>",
"       or N",
"       <sub>",
"        X",
"       </sub>",
"      </td>",
"      <td>",
"       M",
"       <sub>",
"        0",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       3",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       <p>",
"        Bladder/prostate",
"       </p>",
"       <p>",
"        Extremity",
"       </p>",
"       <p>",
"        Cranial parameningeal",
"       </p>",
"       <p>",
"        Other&Delta;",
"       </p>",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       T",
"       <sub>",
"        1",
"       </sub>",
"       or T",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       M",
"       <sub>",
"        0",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       All",
"      </td>",
"      <td>",
"       T",
"       <sub>",
"        1",
"       </sub>",
"       or T",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       a or b",
"      </td>",
"      <td>",
"       N",
"       <sub>",
"        0",
"       </sub>",
"       or N",
"       <sub>",
"        1",
"       </sub>",
"      </td>",
"      <td>",
"       M",
"       <sub>",
"        1",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       T: Tumor stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       N: Regional nodes",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"       M: Metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\" rowspan=\"1\">",
"       <p>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"        : Confined to anatomic site of origin",
"       </p>",
"       <p>",
"        T",
"        <sub>",
"         2",
"        </sub>",
"        : Extension",
"       </p>",
"       <p>",
"        a: &le;5 cm in diameter",
"       </p>",
"       <p>",
"        b: &gt;5 cm in diameter",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"        : Not clinically involved",
"       </p>",
"       <p>",
"        N",
"        <sub>",
"         1",
"        </sub>",
"        : Clinically involved",
"       </p>",
"       <p>",
"        N",
"        <sub>",
"         X",
"        </sub>",
"        : Clinical status unknown",
"       </p>",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       <p>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"        : No distant metastases",
"       </p>",
"       <p>",
"        M",
"        <sub>",
"         1",
"        </sub>",
"        : Distant metastases present",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding parameningeal.",
"     <br>",
"      &bull; Nonbladder/nonprostate.",
"      <br>",
"       &Delta; Includes trunk, retroperitoneum, etc, excluding biliary tract.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lawrence W, Gehan EA, Hays DM, et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987; 5:46; and Lawrence W, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Cancer 1997; 80:1165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7389=[""].join("\n");
var outline_f7_13_7389=null;
var title_f7_13_7390="Classification scoliosis";
var content_f7_13_7390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of scoliosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiopathic*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Early-onset",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infantile",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Juvenile",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Late-onset (adolescent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Congenital vertebral defect*",
"            <sup>",
"             &bull;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemivertebrae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wedge vertebrae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Failure of segmentation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Unilateral (bar)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bilateral (fusion)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Fused ribs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neuromuscular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cerebral palsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Myelomeningocele",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tethered spinal cord",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Spinal cord injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Syringomyelia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diastematomyelia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Friedreich ataxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Charcot-Marie Tooth disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Juvenile spinal muscle atrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Poliomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Myopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Duchenne muscular dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nemaline myopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Facioscapulohumeral dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Limb-girdle muscular dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arthrogryposis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mesenchymal origin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Marfan syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ehlers-Danlos syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Congenital laxity of the joints",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Homocystinuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Direct vertebral trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Irradiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Extravertebral trauma (severe trunk burns or thoracic surgery)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Vertebral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Osteoid osteoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Osteoblastoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Intraspinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Extramedullary (eg, neurofibroma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Intramedullary (eg, astrocytoma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vertebral body infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rickets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Osteogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Schueurmann disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Achondroplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Klippel-Feil syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sprengel deformity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cleidocranial dysostosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hyperphosphatasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypervitaminosis A",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dysautonomia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Juvenile idiopathic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mucopolysaccharidoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leg length discrepancy*",
"            <sup>",
"             &Delta;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary postural scoliosis",
"            <sup>",
"             &Delta;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neurofibromatosis*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most common causes.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      May be associated with other congenital defects (cardiac, genitourinary).",
"      <br>",
"       &Delta; Curve disappears with forward flexion or lying down.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WW. Scoliosis. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.619 and Newton PO, Wenger DR. Idiopathic and congenital scoliosis. In: Lovell and Winter's Pediatric Orthopaedics, 5th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2001. p.677 and Cassar-Pullicino VN, Eisenstein SM. Imaging in scoliosis: what, why and how? Clin Radiol 2002; 57:543.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7390=[""].join("\n");
var outline_f7_13_7390=null;
var title_f7_13_7391="Stool ova and parasites";
var content_f7_13_7391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Appearance and relative sizes of stool ova and parasites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1) Hookworm egg; 2) Whipworm egg (Trichuris trichura); 3) Taenia egg; 4) Entamoeba histolytica cyst; 5) Giardia lamblia cyst; 6) infertile Ascaris lumbricoides egg; 7) red blood cells; and 8) Schistosoma mansoni egg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_13_7391=[""].join("\n");
var outline_f7_13_7391=null;
